var title_f34_2_34848="Ganciclovir: Pediatric drug information";
var content_f34_2_34848=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ganciclovir: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/58/6052?source=see_link\">",
"       Ganciclovir (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/42/13990?source=see_link\">",
"       Ganciclovir (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13331 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_2_34848=[""].join("\n");
var outline_f34_2_34848=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/58/6052?source=related_link\">",
"      Ganciclovir (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/42/13990?source=related_link\">",
"      Ganciclovir (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_2_34849="Patient information: Dystonia (The Basics)";
var content_f34_2_34849=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83332\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/15/16637\">",
"         Most common forms of dystonia",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/8/21633\">",
"         Patient information: Spasmodic dysphonia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/14/13538\">",
"         Patient information: Tremor (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Dystonia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/dystonia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H89087117\">",
"      <span class=\"h1\">",
"       What is dystonia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Dystonia is the term doctors use for a group of disorders that affect muscle movement. There are various types of dystonia that affect specific parts of the body, such as the neck, face, or arms. Dystonia can also affect several different parts of the body at the same time.",
"     </p>",
"     <p>",
"      Dystonia is type of &ldquo;involuntary contraction&rdquo; or &ldquo;spasm&rdquo; of your muscles. This means your muscles move when you are not trying to move them. In dystonia, the spasms last for a long time. This can cause part of your body to twist and stay in an unusual position. For example, your foot might stay turned out, so it drags when you walk.",
"     </p>",
"     <p>",
"      Some types of dystonia start in childhood, others start in adulthood. Some types run in families. There are also types of dystonia that happen with other diseases, such as Parkinson disease.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H89087132\">",
"      <span class=\"h1\">",
"       What are the symptoms of dystonia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Each type of dystonia causes different symptoms (",
"      <a class=\"graphic graphic_table graphicRef83212 \" href=\"mobipreview.htm?16/15/16637\">",
"       table 1",
"      </a>",
"      ). But, in general, all types cause muscle spasms that last a long time. Some people also have &ldquo;tremor,&rdquo; which is the medical term for trembling or shaking that a person cannot control.",
"     </p>",
"     <p>",
"      The symptoms of dystonia affect only the body&rsquo;s movements. People with dystonia usually do not have problems with their ability to think or understand.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H89087147\">",
"      <span class=\"h1\">",
"       Is there a test for dystonia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No, there is no test. But doctors can usually tell if a person has dystonia based on his or her symptoms. Sometimes doctors use tests to make sure that the symptoms are not caused by something else.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H89087162\">",
"      <span class=\"h1\">",
"       How is dystonia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are treatments that can help the symptoms of dystonia. But there is no cure for the problem. Treatment for you will depend on the type of dystonia you have. Treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines &ndash; There are many medicines that can help with the symptoms of dystonia. These medicines come in pill form. Your doctor or nurse will decide which medicine is best for you or your child.",
"       </li>",
"       <li>",
"        Botulinum toxin (often called &ldquo;BoTox&rdquo;) &ndash; BoTox injections (shots) help muscles relax. BoTox can be used in the parts of your body where the symptoms are the worst.",
"       </li>",
"       <li>",
"        Deep brain stimulation (also called DBS)",
"        <strong>",
"        </strong>",
"        &ndash; DBS might be an option for people with severe symptoms who do not get better with medicines or BoTox. People who get DBS must first have surgery to place wires into a part of the brain that helps control muscle movement. The wires are attached to a device that gets implanted under the skin, usually near the collarbone. It sends electrical signals to the brain to reduce muscle spasms. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H89087177\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with dystonia live fairly long lives. But they can have problems doing certain activities. If you or your child has some type of dystonia, ask the doctor about what to expect.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H89087194\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/14/13538?source=see_link\">",
"       Patient information: Tremor (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/8/21633?source=see_link\">",
"       Patient information: Spasmodic dysphonia (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/2/34849?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83332 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-EA0AF42627-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_2_34849=[""].join("\n");
var outline_f34_2_34849=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89087117\">",
"      What is dystonia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89087132\">",
"      What are the symptoms of dystonia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89087147\">",
"      Is there a test for dystonia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89087162\">",
"      How is dystonia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89087177\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89087194\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83332\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/15/16637\">",
"      Most common forms of dystonia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/8/21633?source=related_link\">",
"      Patient information: Spasmodic dysphonia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/14/13538?source=related_link\">",
"      Patient information: Tremor (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_2_34850="Phalen-Dickson sign";
var content_f34_2_34850=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phalen-Dickson sign (bent-knee, hip-flexed posture)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Phalen-Dickson sign demonstrating bent-knee, hip-flexed posture with high-grade spondylolisthesis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bradford DS, Hu SS. Spondyloysis and spondylolisthesis. In: Weinstein SL (Ed). The Pediatric Spine: Principles and Practice. New York: Lippincott-Raven, 1994:585-601. Copyright &copy;1994 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_2_34850=[""].join("\n");
var outline_f34_2_34850=null;
var title_f34_2_34851="Lichenoid chronic GVHD";
var content_f34_2_34851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous papules and plaques, many with a reticulated appearance, are present on the trunk and extremities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_2_34851=[""].join("\n");
var outline_f34_2_34851=null;
var title_f34_2_34852="Pirfenidone: Patient drug information";
var content_f34_2_34852=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pirfenidone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/26/31141?source=see_link\">",
"     see \"Pirfenidone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16237709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Esbriet&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F16254400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F16254959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4179722",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat idiopathic pulmonary fibrosis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F16254401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4179662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pirfenidone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4179682",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Very bad kidney disease or very bad liver disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F16254403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697355",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you smoke, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F16254962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3572837",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight loss.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F16254404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F16254961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F16254402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F16254963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F16254405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88576 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-9F549ED38C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_2_34852=[""].join("\n");
var outline_f34_2_34852=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16237709\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254400\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254959\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254401\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254403\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254962\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254404\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254961\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254402\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254963\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254405\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/26/31141?source=related_link\">",
"      Pirfenidone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_2_34853="Doppler cord prolapse2";
var content_f34_2_34853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Transabdominal ultrasound using colorflow doppler demonstrating the presence of the umbilical cord (funic presentation) just above the cervical canal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_2_34853=[""].join("\n");
var outline_f34_2_34853=null;
var title_f34_2_34854="Ranolazine: Drug information";
var content_f34_2_34854=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ranolazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/49/29460?source=see_link\">",
"    see \"Ranolazine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2528121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ranexa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2528123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Cardiovascular Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2528161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic angina:",
"     </b>",
"     Oral: Initial: 500 mg twice daily; maximum recommended dose: 1000 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Dosage adjustment for ranolazine with concomitant medications:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Diltiazem, erythromycin, verapamil, and other moderate CYP3A inhibitors:",
"     </i>",
"     Ranolazine dose should not exceed 500 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      P-glycoprotein inhibitors (eg, cyclosporine):",
"     </i>",
"     Titrate ranolazine based on clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Dosage adjustment for concomitant medications with ranolazine:",
"     </b>",
"     <i>",
"      Simvastatin:",
"     </i>",
"     Simvastatin dose should not exceed 20 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2528162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Select dose cautiously, starting at the lower end of the dosing range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2528163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There is no dosage adjustments provided in manufacturer&rsquo;s labeling. However, plasma ranolazine levels increased ~50% in patients with varying degrees of renal dysfunction. Patients with severe renal dysfunction had an increase in mean diastolic blood pressure of 10-15 mm Hg. Ranolazine has not been evaluated in patients requiring dialysis.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F2528164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated with any degree of hepatic cirrhosis.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2528167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ranexa&reg;: 500 mg, 1000 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2528139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2528135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without meals. Swallow tablet whole; do not crush, break, or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2528140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic angina",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4431159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ranexa&reg; may be confused with CeleXA&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2528127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;0.5% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Bradycardia (&le;4%), hypotension (&le;4%), orthostatic hypotension (&le;4%), palpitation (&le;4%), peripheral edema (&le;4%), QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (&gt;500 msec: &le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system:   Headache (&le;6%), dizziness (1% to 6%), confusion (&le;4%), vasovagal attacks (&le;4%), vertigo (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Hyperhidrosis (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (&le;9%), abdominal pain (&le;4%), anorexia (&le;4%), dyspepsia (&le;4%), nausea (&le;4%; dose related), vomiting (&le;4%), xerostomia (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular: Weakness (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Otic: Tinnitus (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Hematuria (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &le;0.5% (Limited to important or life-threatening): Angioedema, blood pressure increased, blood urea nitrogen increased, eosinophilia, hallucination, hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     decreased, hypoesthesia, leukopenia, pancytopenia, paresthesia, pruritus, pulmonary fibrosis, rash, renal failure, serum creatinine increased, thrombocytopenia, T-wave amplitude decreased, T-wave changes (notched), torsade de pointes (case report [Morrow, 2007]), tremor",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2528125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatic cirrhosis; concurrent strong CYP3A inhibitors; concurrent CYP3A inducers",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2528143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: Has been shown to prolong QT interval in a dose/plasma concentration-related manner. Hepatically-impaired patients may have a more significant increase in QT interval. The incidence of symptomatic arrhythmias was similar to placebo in one trial (Morrow, 2007). Risk versus benefit should be assessed in patient maintained on a higher dose (2000 mg/day), concurrent use of other QT-prolonging drugs, potassium-channel variants known to cause QT prolongation, personal or family history of prolonged QT, history of congenital long QT syndrome, or acquired prolonged QT.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute angina: Ranolazine does not relieve acute angina attacks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Ranolazine plasma levels increase by 30% in patients with mild (Child-Pugh class A) and by 60% in patients with moderate (Child-Pugh class B) hepatic impairment. Use is contraindicated in patients with any degree of cirrhosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment:  Use with caution in patients with renal dysfunction; plasma levels may increase by 50%. With severe impairment, an elevation in diastolic blood pressure (15 mm Hg) may be observed. Monitor blood pressure in patients with renal dysfunction. Ranolazine has not been evaluated in patients requiring dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Ranolazine is primarily metabolized by CYP3A; use is contraindicated with inducers and strong inhibitors of CYP3A.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; P-glycoprotein inhibitors/substrates: Ranolazine is a substrate for and a moderate inhibitor of P-glycoprotein. Inhibitors of P-glycoprotein may increase serum concentrations of ranolazine. Ranolazine may increase serum concentrations of substrates for P-glycoprotein (eg, digoxin).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT-prolonging drugs: Ranolazine has potential to prolong the QT interval; use caution when administered concomitantly with QT-prolonging drugs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients &ge;75 years of age; they may experience more adverse events (eg, constipation, dizziness, nausea) than younger patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumorigenesis: In APC",
"     <sup>",
"      (Min/+)",
"     </sup>",
"     mice, an established model of spontaneous intestinal tumorigenesis, ranolazine was shown to have a dose-dependent increase in the number of intestinal tumors.  Clinical significance of this effect in humans is unknown.  However, use caution when administering ranolazine to patients with a history of malignant neoplasms or adenomatous polyps.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2528147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP3A4 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2528146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May increase the serum concentration of Ranolazine. Management: Limit ranolazine dose to a maximum of 500 mg twice daily when used with diltiazem or verapamil.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Ranolazine. Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Ranolazine may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Ranolazine may enhance the myopathic (rhabdomyolysis) effect of Lovastatin. Ranolazine may increase the serum concentration of Lovastatin. Ranolazine may also enhance the distribution of lovastatin to specific cells/tissues/organs where P-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Ranolazine may increase the serum concentration of Simvastatin.  Management: Avoid the concurrent use of ranolazine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Ranolazine may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6814825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Grapefruit, grapefruit juice, or grapefruit-containing products may increase the serum concentration of ranolazine. Management: Avoid grapefruit-containing products or dose adjustment of ranolazine may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may decrease the serum concentration of ranolazine. Management: Avoid St John&rsquo;s wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6004810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2528141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were observed in animal studies. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2528142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6814824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2528157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals. Limit the use of grapefuit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Ranexa Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (60): $290.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (60): $476.51",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2528165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline and follow up ECG to evaluate QT interval; blood pressure in patients with renal dysfunction; correct and maintain serum potassium in normal limits",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ranexa (AT, CH, CZ, DE, EE, FR, GB, GR, IE, NL, PL, PT, SE);",
"     </li>",
"     <li>",
"      Ranx (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2528158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ranolazine exerts antianginal and anti-ischemic effects without changing hemodynamic parameters (heart rate or blood pressure). At therapeutic levels, ranolazine inhibits the late phase of the inward sodium channel (late I",
"     <sub>",
"      Na",
"     </sub>",
"     ) in ischemic cardiac myocytes during cardiac repolarization reducing intracellular sodium concentrations and thereby reducing calcium influx via Na",
"     <sup>",
"      +",
"     </sup>",
"     -Ca",
"     <sup>",
"      2+",
"     </sup>",
"     exchange. Decreased intracellular calcium reduces ventricular tension and myocardial oxygen consumption. It is thought that ranolazine produces myocardial relaxation and reduces anginal symptoms through this mechanism although this is uncertain. At higher concentrations, ranolazine inhibits the rapid delayed rectifier potassium current (I",
"     <sub>",
"      Kr",
"     </sub>",
"     ) thus prolonging the ventricular action potential duration and subsequent prolongation of the QT interval.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2528133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Highly variable; ranolazine is a substrate of P-glycoprotein; concurrent use of P-glycoprotein inhibitors may increase absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~62%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP3A (major) and 2D6 (minor); gut",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 35% to 55%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Ranolazine: Terminal: 7 hours; Metabolites (activity undefined): 6-22 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Primarily urine (75% mostly as metabolites); feces (25% mostly as metabolites); in feces and urine, &lt;5% to 7% excreted unchanged",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abdallah H and Jerling M,  &ldquo;Effect of Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ranolazine Sustained Release Tablets,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2005, 45(7):802-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/2/34854/abstract-text/15951470/pubmed\" id=\"15951470\" target=\"_blank\">",
"        15951470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chaitman BR, Pepine CJ, Parker JO, et al, &ldquo;Effects of Ranolazine With Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients With Severe Chronic Angina. A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(3):309-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/2/34854/abstract-text/14734593/pubmed\" id=\"14734593\" target=\"_blank\">",
"        14734593",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chaitman BR, Skettino SL, Parker JO, et al, &ldquo;Anti-ischemic Effects and Long-term Survival During Ranolazine Monotherapy in Patients With Chronic Severe Angina,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      ,  2004, 43(8):1375-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/2/34854/abstract-text/15093870/pubmed\" id=\"15093870\" target=\"_blank\">",
"        15093870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dobesh PP and Trujillo TC, &ldquo;Ranolazine: A New Option in the Management of Chronic Stable Angina,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2007, 27(12):1659-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/2/34854/abstract-text/18041887/pubmed\" id=\"18041887\" target=\"_blank\">",
"        18041887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/2/34854/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jerling M and Abdallah H, &ldquo;Effect of Renal Impairment on Multiple-Dose Pharmacokinetics of Extended Release Ranolazine,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2005, 78(3):288-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/2/34854/abstract-text/16153399/pubmed\" id=\"16153399\" target=\"_blank\">",
"        16153399",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren MJ, Crager MR, and Sweeney M, &ldquo;Long-term Safety of a Novel Antianginal Agent in Patients with Severe Chronic Stable Angina: The Ranolazine Open Label Experience (ROLE),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 49(10):1027-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/2/34854/abstract-text/17349881/pubmed\" id=\"17349881\" target=\"_blank\">",
"        17349881",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al, &ldquo;Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non-ST-Elevation Acute Coronary Syndromes. The MERLIN-TIMI 36 Randomized Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2007, 297(16):1775-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/2/34854/abstract-text/17456819/pubmed\" id=\"17456819\" target=\"_blank\">",
"        17456819",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scirica BM, Morrow DA, Hod H, et al, &ldquo;Effect of ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non ST-Segment Elevation acute Coronary Syndrome: Results From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(15):1647-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/2/34854/abstract-text/17804441/pubmed\" id=\"17804441\" target=\"_blank\">",
"        17804441",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stone PH, Gratsiansky NA, Blokhin A, et al, &ldquo;Antianginal Efficacy of Ranolazine When Added to Treatment With Amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) Trial,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(3):566-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/2/34854/abstract-text/16875985/pubmed\" id=\"16875985\" target=\"_blank\">",
"        16875985",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suckow MA, Gutierrez LS, Risatti CA, et al, &ldquo;The Anti-ischemia Agent Ranolazine Promotes the Development of Intestinal Tumors in APC(Min/+) Mice,&rdquo;",
"      <i>",
"       Cancer Lett",
"      </i>",
"      , 2004, 209(2):165-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/2/34854/abstract-text/15159018/pubmed\" id=\"15159018\" target=\"_blank\">",
"        15159018",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10262 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_2_34854=[""].join("\n");
var outline_f34_2_34854=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528121\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528123\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528161\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528162\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528163\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528164\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528167\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528139\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528135\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528140\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4431159\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528127\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528125\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528143\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528147\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528146\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6814825\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6004810\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528141\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528142\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6814824\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528157\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422174\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528165\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390213\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528158\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528133\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10262\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10262|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/49/29460?source=related_link\">",
"      Ranolazine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_2_34855="Open-angle glaucoma: Treatment";
var content_f34_2_34855=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Open-angle glaucoma: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/2/34855/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/2/34855/contributors\">",
"     Deborah S Jacobs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/2/34855/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/2/34855/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/2/34855/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/2/34855/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/2/34855/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6891039\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glaucoma is a group of eye diseases traditionally characterized by elevated intraocular pressure (IOP). However, glaucoma is more accurately defined as an optic neuropathy involving a characteristic atrophy of the optic nerve head, which may or may not be accompanied by elevated IOP. In open-angle glaucoma, optic nerve damage results in a progressive loss of retinal ganglion cell axons, which is manifested initially as visual field loss and, ultimately, irreversible blindness if left untreated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will focus on the treatment of primary open-angle glaucoma, where the etiology is unknown. Treatment of known causes (eg, uveitis, trauma, glucocorticoid therapy), in addition to lowering IOP, should be considered in patients with secondary open-angle glaucoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/10/10407?source=see_link\">",
"     \"Uveitis: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link&amp;anchor=H8#H8\">",
"     \"Major side effects of systemic glucocorticoids\", section on 'Eye'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glaucoma in children, angle-closure glaucoma, and epidemiology and diagnosis of open-angle glaucoma are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41463?source=see_link\">",
"     \"Overview of glaucoma in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9063?source=see_link\">",
"     \"Angle-closure glaucoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15289?source=see_link\">",
"     \"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6891046\">",
"    <span class=\"h1\">",
"     GOALS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lowering intraocular pressure (IOP) has been shown to reduce the risk of glaucomatous progression of visual field loss",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    optic disc changes and is the primary goal of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In a meta-analysis of two randomized trials of patients with open-angle glaucoma, those randomly assigned to IOP lowering treatment were less likely to have progression of visual field",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    optic disc deterioration compared to those randomly assigned to placebo (HR 0.65, 95% CI 0.49-0.87) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors such as blood supply, nerve metabolism, and extracellular matrix likely play a role in the progressive optic neuropathy of glaucoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/4\">",
"     4",
"    </a>",
"    ]. However, treatment targeting these other factors in patients with open-angle glaucoma has not been well-studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy must be individualized, taking into account the patient's disease state, target pressure, and medical comorbidities. Patient education, informed participation in decision making, and emphasis on compliance are particularly important since open-angle glaucoma is largely asymptomatic. (See",
"    <a class=\"local\" href=\"#H6891123\">",
"     'Compliance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447093519\">",
"    <span class=\"h1\">",
"     INITIATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clear consensus regarding a threshold IOP for the initiation of open-angle glaucoma treatment. There are patients with IOP 22 to 24 mmHg who have thicker corneas and healthy optic nerves by field",
"    <span class=\"nowrap\">",
"     testing/imaging",
"    </span>",
"    and do not require treatment. Most clinicians would initiate treatment for a patient with two instances of IOP &gt;25 mmHg, while some would do so for IOP &gt;22 mmHg. Alternatively, a patient with an IOP of 18 who has cupping and field loss should be treated for glaucoma.",
"   </p>",
"   <p>",
"    Patients at high risk for visual field deterioration should also be treated. In an exploratory analysis of a randomized trial, patients with disc hemorrhage had more rapid visual field deterioration over a mean of 12 years than eyes without disc hemorrhage (mean rate of change -0.17 versus -0.07) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, patients with disc hemorrhage require a more aggressive approach to therapy.",
"   </p>",
"   <p>",
"    Open-angle glaucoma tends to be bilateral, but can be quite asymmetric. The decision to treat is made for each eye rather than for each patient. Monocular treatment may be indicated, at least initially.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447093482\">",
"    <span class=\"h1\">",
"     TYPES OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;IOP can be lowered by pharmacologic therapy, laser therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6891053\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical medications work either by increasing aqueous outflow (prostaglandins, alpha adrenergic agonists, cholinergic agonists) or by decreasing aqueous production (alpha adrenergic agonists, beta blockers, carbonic anhydrase inhibitors) (",
"    <a class=\"graphic graphic_table graphicRef76771 \" href=\"mobipreview.htm?27/9/27804\">",
"     table 1",
"    </a>",
"    ). Systemic carbonic anhydrase inhibitors also decrease aqueous production.",
"   </p>",
"   <p>",
"    Pharmacologic therapy often requires administration of multiple medications. Many older drugs require dosing three or four times a day. Newer drugs can be administered once or twice daily but these drugs can be expensive in the US. Glaucoma medications have potential side effects and may be particularly inconvenient to use for some elderly or incapacitated patients.",
"   </p>",
"   <p>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6891060\">",
"    <span class=\"h3\">",
"     Prostaglandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The topical prostaglandins are increasingly chosen over topical beta blockers and other medications as initial therapy in open-angle glaucoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/7\">",
"     7",
"    </a>",
"    ]. Prostaglandins have been consistently shown in randomized trials to be effective and well tolerated, with few systemic side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. As an example, in one meta-analysis of randomized trials comparing prostaglandins and beta blockers in patients with primary open-angle glaucoma,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/42/41635?source=see_link\">",
"     latanoprost",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44115?source=see_link\">",
"     bimatoprost",
"    </a>",
"    were found to have significantly greater reductions in IOP compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/2/31776?source=see_link\">",
"     timolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/8\">",
"     8",
"    </a>",
"    ]. Although all of the prostaglandins were associated with hyperemia, latanoprost was less likely to cause hyperemia compared to bimatoprost.",
"   </p>",
"   <p>",
"    Generic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/42/41635?source=see_link\">",
"     latanoprost",
"    </a>",
"    is available in the US as of March 2011. Proprietary prostaglandins are expensive, which may impact drug adherence. Prostaglandins do have the advantage of once daily dosing.",
"    <br/>",
"   </p>",
"   <p>",
"    In addition to conjunctival hyperemia, ocular side effects include eye irritation, increase in the number and length of eyelashes, and changes in iris and lash pigmentation; the latter two are most notable if only one eye is treated. Local irritation (itching and dryness) may be due to corneal irritation from benzalkonium chloride, used as a preservative in several preparations.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/51/5939?source=see_link\">",
"     Tafluprost",
"    </a>",
"    is available in the US as of April 2012 (and has been available in other countries previously) and contains no preservative. However, refrigeration and care in handling the single use packets is needed to minimize risk of infection, with immediate discard of any unused solution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6891067\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-blockers have traditionally been considered first-line therapy, but more recent publications promote prostaglandins for initial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Randomized trials have found that topical beta blockers (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/2/31776?source=see_link\">",
"     timolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/11/32944?source=see_link\">",
"     betaxolol",
"    </a>",
"    ) can lower IOP, have a long duration of action which allows once or twice daily dosing, and are associated with few ocular side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. As an example, one meta-analysis of randomized trials found a weak, borderline benefit of beta blockers in preventing incidence of visual field deficits in patients with primary open-angle glaucoma or ocular hypertension, compared to placebo or no treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <br/>",
"    Major side effects are similar to those associated with systemic beta blocker therapy, including worsening of heart failure, bradycardia, heart block, and increased airway resistance and topical beta blockers are contraindicated in some patients with cardiac or pulmonary disease. Airway obstruction has been reported with topical beta blocker therapy even in patients who do not have a history of airway disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6891074\">",
"    <span class=\"h3\">",
"     Other drugs",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alpha adrenergic agonists (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/32/15877?source=see_link\">",
"       brimonidine",
"      </a>",
"      ) appear to be similarly effective to beta blockers in lowering IOP in open-angle glaucoma, but are associated with a number of ocular side effects including allergic conjunctivitis, hyperemia, and ocular pruritus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/21\">",
"       21",
"      </a>",
"      ]. The nonselective agents (epinephrine) also may be associated with arrhythmia, hypertension, and tachycardia.",
"      <br/>",
"      <br/>",
"      Alpha adrenergic agonists may have a role in treatment of normal pressure glaucoma. In a randomized trial of 99 patients with open-angle glaucoma and IOP &lt;22 mmHg, those assigned to brimonidine were less likely to experience progression of visual field deficit compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/2/31776?source=see_link\">",
"       timolol",
"      </a>",
"      , after a mean follow-up of 30 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/22\">",
"       22",
"      </a>",
"      ]. However, patients receiving brimonidine were more likely to drop out, most commonly due to localized ocular allergy. As the mean IOP in both arms was similar throughout the study period, any effectiveness of brimonidine in delaying or preventing visual field progression is likely due to a mechanism not related to IOP reduction.",
"     </li>",
"     <li>",
"      Systemic carbonic anhydrase inhibitors have largely been replaced by newer topical preparations that have fewer systemic side effects. Topical carbonic anhydrase inhibitors do not appear to be as effective in treating open-angle glaucoma compared to other pharmacologic therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cholinergic agonists have fewer systemic adverse effects than beta-blockers, but ocular side effects such as fixed, small pupils, myopia, and increased subjective visual disturbance related to coexistent cataract have decreased the popularity of these drugs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6891081\">",
"    <span class=\"h2\">",
"     Laser therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laser therapy (trabeculoplasty) increases aqueous outflow. Randomized trials confirm that it is successful in lowering IOP for patients with open angle glaucoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/23\">",
"     23",
"    </a>",
"    ]. A review of the literature, prepared for the American Academy of Ophthalmology, found high-quality evidence that the long-term efficacy of initial argon laser trabeculoplasty is comparable with initial medical therapy for open-angle glaucoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/24\">",
"     24",
"    </a>",
"    ]. The report found no literature to establish the superiority of newer forms of laser trabeculoplasty over the argon laser. The cost-effectiveness of laser therapy, compared to prostaglandin medications for newly-diagnosed, mild open-angle glaucoma, is about equivalent in one modelling study; laser therapy may be slightly more cost-effective if, as expected, medical compliance in community settings is lower than reported in clinical trials while medication provides somewhat greater value assuming optimal adherence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6891088\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical therapy involves the creation of a filtration bleb to allow egress of aqueous humor from the eye. This is an alternative route to the normal pathway via the trabecular meshwork and the canal of Schlemm (",
"    <a class=\"graphic graphic_figure graphicRef71234 \" href=\"mobipreview.htm?10/60/11201\">",
"     figure 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    Filtration surgery not uncommonly fails due to excessive scar tissue formation. There are reports of the use of adjuncts before, during, or after surgery, such as beta irradiation and antimetabolites (5-fluorouracil and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C), to increase the rate of surgical success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. There is great variation in use and choice of adjuncts worldwide, and adjuncts can be associated with a higher complication rate. For example, beta irradiation at the time of trabeculectomy can minimize scar tissue formation and increase the likelihood that surgery will effectively lower the IOP, but increases the risk of cataract formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical therapy of advanced glaucoma can involve the placement of mechanical shunts (also called \"valves\"). Shunts are typically only placed in patients with advanced disease in whom medical and laser therapies are inadequate and who have an underlying diagnosis that increases the risk of failure of conventional surgery (eg, neovascular glaucoma, cornea transplant, iridocorneal endothelial [ICE] syndrome). An expanding role for may be emerging, including use in eyes that have had previous conjunctival incisions (cataract extraction), based on five year outcomes from a trial comparing tube shunts and trabeculectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/29\">",
"     29",
"    </a>",
"    ]. There are a number of types of shunts, but there is no strong evidence supporting the superiority of one shunt over another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical therapy is associated with a number of attendant risks and complications, including cataract and permanent loss of vision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6891095\">",
"    <span class=\"h1\">",
"     CHOOSING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the US, medical therapy is generally undertaken before laser or surgical therapy. A panel of US glaucoma experts recommended medical therapy as initial treatment, using RAND (Research And Development) Corporation consensus methodology in combination with an evidence-based review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/31\">",
"     31",
"    </a>",
"    ]. A subsequent American Academy of Ophthalmology technology assessment found that initial argon laser trabeculoplasty has acceptable long-term efficacy compared with initial medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/24\">",
"     24",
"    </a>",
"    ]. Two subsequent systematic reviews concluded that it is unclear whether medical or surgical treatments are more effective at preventing visual deterioration and improving patient-reported outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. All available studies have methodologic weaknesses. We recommend pharmacologic or laser therapy as first-line treatment of open-angle glaucoma, especially in light of well-documented complications associated with surgical therapy.",
"   </p>",
"   <p>",
"    A representative trial is the Collaborative Initial Glaucoma Treatment Study (CIGTS) of 607 patients with newly diagnosed open-angle glaucoma that examined the benefits of medical versus surgical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The primary outcome, visual field loss, did not differ between the two groups at four to five years of follow-up. Quality of life measures were also similar. The intraocular pressure in the medical and surgical therapy groups averaged 17 to 18 mmHg and 14 to 15 mmHg, respectively. The patients who underwent surgery (trabeculectomy) had a higher rate of cataract requiring removal and more local eye symptoms. There was also minimal change in visual field loss between the medical and surgical treatment arms at nine-year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/36\">",
"     36",
"    </a>",
"    ]. However, initial surgery was beneficial in a subset of patients with severe visual field loss at baseline and was detrimental in those patients with diabetes. Patients undergoing surgery were still at increased risk of cataract requiring removal after a median follow-up of eight years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If medical therapy has been chosen as initial treatment for open-angle glaucoma, prostaglandins are generally considered first-line therapy. Most [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/8-10\">",
"     8-10",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/16\">",
"     16",
"    </a>",
"    ], meta-analyses have found prostaglandins to be more effective than beta blockers, carbonic anhydrase inhibitors, and alpha adrenergic agonists for the treatment of open-angle glaucoma. In addition, initial therapy with prostaglandins has been suggested by consensus panels, in part due to the low side effect profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/31,38\">",
"     31,38",
"    </a>",
"    ]. Beta blockers may be more appropriate as initial therapy for those patients who cannot afford a topical prostaglandin.",
"   </p>",
"   <p>",
"    Combining drops from different classes (ie, beta blocker plus prostaglandin, or beta blocker plus carbonic anhydrase inhibitor) can cause a greater reduction in the intraocular pressure than monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/8,39,40\">",
"     8,39,40",
"    </a>",
"    ], and several drugs are available as fixed combination products. Adding a second medication is reasonable if initial monotherapy is not effective.",
"   </p>",
"   <p>",
"    Patients with advanced open-angle glaucoma who do not respond to medications or laser therapy should be offered surgical intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal therapy for patients with normal-pressure glaucoma remains uncertain, but control of IOP remains one major goal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/41\">",
"     41",
"    </a>",
"    ]. Thus, similar treatment strategies are generally applied for patients with high- and normal-pressure glaucoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6891109\">",
"    <span class=\"h1\">",
"     TARGET INTRAOCULAR PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once glaucoma is diagnosed, the treating clinician typically defines a target pressure at which no further damage is likely to occur for that eye. A damaged nerve, as assessed by imaging",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    field testing, is likely to require a lower target pressure.",
"   </p>",
"   <p>",
"    There are no standard guidelines for the optimal target IOP. The Early Manifest Glaucoma Trial (EMGT) study found a graded effect of IOP lowering and risk of visual field loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/42\">",
"     42",
"    </a>",
"    ]. Ophthalmologists must determine appropriate target pressures for individual patients and individual eyes, with adjustments based on close follow-up of visual fields and evaluation for cup progression. The target pressure must be lowered if nerve damage occurs despite achieving the target. Typically patients with more advanced disc damage and field loss need lower target pressures.",
"   </p>",
"   <p>",
"    Data from EMGT and the Collaborative Initial Glaucoma Treatment Study (CIGTS) have suggested a target IOP of &ge;25 to 30 percent below initial IOP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/34,35,42\">",
"     34,35,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6891116\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with open-angle glaucoma require lifetime monitoring and therapy. The interval for monitoring IOP, the optic disc, and visual fields varies with the extent of damage, whether or not there is recent progression of damage, the stability of IOP control, and the level of patient compliance. Most patients with a diagnosis of open-angle glaucoma are seen at least twice yearly. Patients with progression may be tested every few months until it is clear that progression has stopped. Patients may be seen every two to four weeks during a period of time in which therapy is being escalated for progression or when there is poor control of IOP.",
"   </p>",
"   <p>",
"    Patients receiving surgery, even those who achieve successful &lsquo;filtration,&rsquo; can require frequent monitoring for failure of the filtration bleb and monitoring of cataract formation. (See",
"    <a class=\"local\" href=\"#H6891088\">",
"     'Surgery'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6891123\">",
"    <span class=\"h1\">",
"     COMPLIANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapy of open-angle glaucoma often is characterized by poor compliance, in part because the disease is asymptomatic. One study found that 24 percent of patients were noncompliant with drops four times a day, and 18 percent were noncompliant with drops two times a day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients often fail to reschedule missed visits, only rescheduling when their prescription drops can no longer be refilled. Glaucoma therapy and monitoring are often neglected by patients, family, and caregivers as patients age, become less able to care for themselves, and more apparent concerns move to the forefront. Prospective population-based studies of glaucoma tend to be confounded by high dropout rates for these reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/44\">",
"     44",
"    </a>",
"    ]. The primary care clinician can play an important role in encouraging compliance.",
"   </p>",
"   <p>",
"    Bottles containing ophthalmic drops generally have different color caps depending on the pharmacologic class. These colors differ substantially between countries. Clinicians should check bottles to ensure proper administration, when patients are prescribed more than one topical ophthalmic medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447094325\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials that investigated the effect of lowering IOP in patients with elevated IOP without visual defects have found some benefit in delaying or preventing the onset of open-angle glaucoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/2,45,46\">",
"     2,45,46",
"    </a>",
"    ]. IOP testing remains the most available and best studied means of screening for glaucoma. However, no diagnostic test has adequate sensitivity or specificity for screening in the general population, alone or in combination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34855/abstract/47\">",
"     47",
"    </a>",
"    ]. It remains unclear which populations should be screened, what screening tests should be performed, and with what frequency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15289?source=see_link&amp;anchor=H11#H11\">",
"     \"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15289?source=see_link&amp;anchor=H447095064#H447095064\">",
"     \"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/13/2258?source=see_link\">",
"       \"Patient information: Glaucoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6891144\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lowering intraocular pressure is the primary goal of therapy, which has been shown to reduce the progression of visual field loss. Intraocular pressure (IOP) can be lowered by pharmacologic therapy, laser therapy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgery. (See",
"      <a class=\"local\" href=\"#H6891046\">",
"       'Goals of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no clear consensus regarding a threshold IOP for the initiation of treatment. We suggest initiating treatment for patients with two instances of IOP &gt;25 mmHg (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H447093519\">",
"       'Initiation of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the decision has been made to treat a patient with open-angle glaucoma, we recommend pharmacologic or laser therapy as first-line treatment rather than surgery (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6891095\">",
"       'Choosing therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If pharmacologic therapy is chosen, we suggest topical prostaglandins as first-line pharmacologic therapy rather than other topical or systemic medications (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6891095\">",
"       'Choosing therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combining drops from different classes (ie, beta blocker plus prostaglandin or beta blocker plus carbonic anhydrase inhibitor) can cause a greater reduction in the intraocular pressure than monotherapy. Adding a second medication is reasonable if initial monotherapy is not effective. (See",
"      <a class=\"local\" href=\"#H6891095\">",
"       'Choosing therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The target intraocular pressure and subsequent monitoring intervals depends on several factors, including the extent of intraocular damage, whether or not there is recent progression of damage, the stability of intraocular pressure, and the level of patient compliance. (See",
"      <a class=\"local\" href=\"#H6891109\">",
"       'Target intraocular pressure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6891116\">",
"       'Monitoring'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6891123\">",
"       'Compliance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/1\">",
"      Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004; 363:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/2\">",
"      Maier PC, Funk J, Schwarzer G, et al. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ 2005; 331:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/3\">",
"      Hyman L, Heijl A, Leske MC, et al. Natural history of intraocular pressure in the early manifest glaucoma trial: A 6-year follow-up. Arch Ophthalmol 2010; 128:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/4\">",
"      Kwon YH, Fingert JH, Kuehn MH, Alward WL. Primary open-angle glaucoma. N Engl J Med 2009; 360:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/5\">",
"      He Y, Leung KW, Zhang YH, et al. Mitochondrial complex I defect induces ROS release and degeneration in trabecular meshwork cells of POAG patients: protection by antioxidants. Invest Ophthalmol Vis Sci 2008; 49:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/6\">",
"      De Moraes CG, Demirel S, Gardiner SK, et al. Rate of visual field progression in eyes with optic disc hemorrhages in the ocular hypertension treatment study. Arch Ophthalmol 2012; 130:1541.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension. 2009. Available at: file://publications.nice.org.uk/glaucoma-cg85/introduction (Accessed on May 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/8\">",
"      Orme M, Collins S, Dakin H, et al. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension. Curr Med Res Opin 2010; 26:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/9\">",
"      van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005; 112:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/10\">",
"      Fung AT, Reid SE, Jones MP, et al. Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. Br J Ophthalmol 2007; 91:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/11\">",
"      Evans DW, Bartlett JD, Houde B, et al. Latanoprost-induced stabilization of central visual function in patients with primary open-angle glaucoma. J Ocul Pharmacol Ther 2008; 24:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/12\">",
"      Tafluprost (Zioptan) - a new topical prostaglandin for glaucoma. Med Lett Drugs Ther 2012; 54:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/13\">",
"      Hedman K, Alm A, Gross RL. Pooled-data analysis of three randomized, double-masked, six-month studies comparing intraocular pressure-reducing effects of latanoprost and timolol in patients with ocular hypertension. J Glaucoma 2003; 12:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/14\">",
"      van der Valk R, Webers CA, Lumley T, et al. A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol 2009; 62:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/15\">",
"      Cheng JW, Cai JP, Li Y, Wei RL. A meta-analysis of topical prostaglandin analogs in the treatment of chronic angle-closure glaucoma. J Glaucoma 2009; 18:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/16\">",
"      Vass C, Hirn C, Sycha T, et al. Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database Syst Rev 2007; :CD003167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/17\">",
"      Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 121:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/18\">",
"      Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology 2009; 116:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/19\">",
"      Kirwan JF, Nightingale JA, Bunce C, Wormald R. Beta blockers for glaucoma and excess risk of airways obstruction: population based cohort study. BMJ 2002; 325:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/20\">",
"      Kirwan JF, Nightingale JA, Bunce C, Wormald R. Do selective topical beta antagonists for glaucoma have respiratory side effects? Br J Ophthalmol 2004; 88:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/21\">",
"      Loon SC, Liew G, Fung A, et al. Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma. Clin Experiment Ophthalmol 2008; 36:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/22\">",
"      Krupin T, Liebmann JM, Greenfield DS, et al. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 2011; 151:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/23\">",
"      Rolim de Moura C, Paranhos A Jr, Wormald R. Laser trabeculoplasty for open angle glaucoma. Cochrane Database Syst Rev 2007; :CD003919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/24\">",
"      Samples JR, Singh K, Lin SC, et al. Laser trabeculoplasty for open-angle glaucoma: a report by the american academy of ophthalmology. Ophthalmology 2011; 118:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/25\">",
"      Stein JD, Kim DD, Peck WW, et al. Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma. Arch Ophthalmol 2012; 130:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/26\">",
"      Palanca-Capistrano AM, Hall J, Cantor LB, et al. Long-term outcomes of intraoperative 5-fluorouracil versus intraoperative mitomycin C in primary trabeculectomy surgery. Ophthalmology 2009; 116:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/27\">",
"      Reibaldi A, Uva MG, Longo A. Nine-year follow-up of trabeculectomy with or without low-dosage mitomycin-c in primary open-angle glaucoma. Br J Ophthalmol 2008; 92:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/28\">",
"      Kirwan JF, Rennie C, Evans JR. Beta radiation for glaucoma surgery. Cochrane Database Syst Rev 2009; :CD003433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/29\">",
"      Gedde SJ, Schiffman JC, Feuer WJ, et al. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol 2012; 153:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/30\">",
"      Minckler DS, Vedula SS, Li TJ, et al. Aqueous shunts for glaucoma. Cochrane Database Syst Rev 2006; :CD004918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/31\">",
"      Singh K, Lee BL, Wilson MR, Glaucoma Modified RAND-Like Methodology Group. A panel assessment of glaucoma management: modification of existing RAND-like methodology for consensus in ophthalmology. Part II: Results and interpretation. Am J Ophthalmol 2008; 145:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/32\">",
"      Burr J, Azuara-Blanco A, Avenell A, Tuulonen A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst Rev 2012; 9:CD004399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/33\">",
"      Boland MV, Ervin AM, Friedman DS, et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013; 158:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/34\">",
"      Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/35\">",
"      Janz NK, Wren PA, Lichter PR, et al. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology 2001; 108:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/36\">",
"      Musch DC, Gillespie BW, Lichter PR, et al. Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. Ophthalmology 2009; 116:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/37\">",
"      Musch DC, Gillespie BW, Niziol LM, et al. Cataract extraction in the collaborative initial glaucoma treatment study: incidence, risk factors, and the effect of cataract progression and extraction on clinical and quality-of-life outcomes. Arch Ophthalmol 2006; 124:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/38\">",
"      Drugs for some common eye disorders. Treat Guidel Med Lett 2010; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/39\">",
"      Webers CA, van der Valk R, Schouten JS, et al. Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol: a meta-analysis of randomized clinical trials. Ophthalmology 2007; 114:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/40\">",
"      Higginbotham EJ, Olander KW, Kim EE, et al. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol 2010; 128:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/41\">",
"      Shields MB. Normal-tension glaucoma: is it different from primary open-angle glaucoma? Curr Opin Ophthalmol 2008; 19:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/42\">",
"      Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/43\">",
"      Kass MA, Gordon M, Morley RE Jr, et al. Compliance with topical timolol treatment. Am J Ophthalmol 1987; 103:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/44\">",
"      Armaly MF, Krueger DE, Maunder L, et al. Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects. Arch Ophthalmol 1980; 98:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/45\">",
"      Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/46\">",
"      Epstein DL, Krug JH Jr, Hertzmark E, et al. A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects. Ophthalmology 1989; 96:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34855/abstract/47\">",
"      Mowatt G, Burr JM, Cook JA, et al. Screening tests for detecting open-angle glaucoma: systematic review and meta-analysis. Invest Ophthalmol Vis Sci 2008; 49:5373.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15695 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-09F22AFDA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_2_34855=[""].join("\n");
var outline_f34_2_34855=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6891144\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6891039\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6891046\">",
"      GOALS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H447093519\">",
"      INITIATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H447093482\">",
"      TYPES OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6891053\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6891060\">",
"      - Prostaglandins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6891067\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6891074\">",
"      - Other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6891081\">",
"      Laser therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6891088\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6891095\">",
"      CHOOSING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6891109\">",
"      TARGET INTRAOCULAR PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6891116\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6891123\">",
"      COMPLIANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H447094325\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6891144\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/15695\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/15695|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/60/11201\" title=\"figure 1\">",
"      Angle anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/15695|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/9/27804\" title=\"table 1\">",
"      Agents that reduce intraocular pressure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9063?source=related_link\">",
"      Angle-closure glaucoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15289?source=related_link\">",
"      Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41463?source=related_link\">",
"      Overview of glaucoma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/13/2258?source=related_link\">",
"      Patient information: Glaucoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/10/10407?source=related_link\">",
"      Uveitis: Treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_2_34856="Allergic conjunctivitis";
var content_f34_2_34856=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Allergic conjunctivitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/2/34856/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/2/34856/contributors\">",
"     Reza Dana, MD, MPH, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/2/34856/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/2/34856/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/2/34856/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/2/34856/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/2/34856/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic conjunctivitis is a relatively benign ocular disease that causes significant suffering and use of healthcare resources, although it does not threaten vision. Ocular allergy is estimated to affect at least 20 percent of the population on an annual basis, and the incidence is increasing. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of allergic conjunctivitis is presented here. Allergic rhinitis and an overview of causes of conjunctivitis are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37834?source=see_link\">",
"     \"Pharmacotherapy of allergic rhinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20760?source=see_link\">",
"     \"Conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic conjunctivitis is predominantly a disease of young adults, with an average age of onset of 20 years of age. Symptoms tend to decrease with age. Approximately one-half of patients have a personal or family history of other allergic conditions, such as allergic rhinitis, atopic dermatitis, and asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic eye disease primarily affects the conjunctiva. The signs and symptoms include itching, tearing, conjunctival edema, hyperemia, watery discharge, burning, and photophobia (",
"    <a class=\"graphic graphic_picture graphicRef57240 \" href=\"mobipreview.htm?14/20/14670\">",
"     picture 1",
"    </a>",
"    ). Eyelid edema is also common. Symptoms are usually bilateral; however, one eye can be affected more than the other.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of allergic conjunctivitis is usually made clinically. A number of tests can be performed in patients suspected of having allergic conjunctivitis, although these are usually limited to academic or confirmatory purposes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conjunctival scrapings - Conjunctival scrapings may be evaluated for the presence of eosinophils. Eosinophils are present in scrapings in up to 80 percent of patients with acute allergic conjunctivitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/5\">",
"       5",
"      </a>",
"      ]. However, since eosinophils are situated deep in the conjunctiva, vigorous scraping of the conjunctiva may be necessary to confirm their presence.",
"     </li>",
"     <li>",
"      IgE levels - Tear film levels of IgE are raised in patients with allergic conjunctivitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/6\">",
"       6",
"      </a>",
"      ]. Furthermore, serum levels of IgE are known to be elevated when the tear film levels of IgE are raised [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mast cell activity - Mast cell activity can be measured by immunoassay testing of tears for tryptase, which is unique to mast cells. Histamine levels can also be measured in tears. However, these measurements will vary depending upon the amount of time elapsed from the conjunctival challenge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TYPES OF ALLERGIC CONJUNCTIVITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic conjunctivitis can be subdivided into three specific conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute allergic conjunctivitis",
"     </li>",
"     <li>",
"      Seasonal allergic conjunctivitis (SAC)",
"     </li>",
"     <li>",
"      Perennial allergic conjunctivitis (PAC)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each is associated with specific clinical features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Acute allergic conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute allergic conjunctivitis is a sudden-onset hypersensitivity reaction caused by environmental exposure, usually to a known allergen, such as cat dander [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/8\">",
"     8",
"    </a>",
"    ]. It is characterized by intense episodes of itching, hyperemia, tearing, chemosis, and eyelid edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/9\">",
"     9",
"    </a>",
"    ]. Symptoms can be severe and debilitating, although they usually resolve within 24 hours of removal of the allergen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Seasonal allergic conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seasonal allergic conjunctivitis (SAC) goes by several other names, including allergic conjunctivitis, hay-fever type conjunctivitis, or allergic rhinoconjunctivitis. It is a mild form of ocular allergy, and it is frequently associated with rhinitis. SAC typically has a less dramatic onset compared to acute allergic conjunctivitis, and a more predictable and chronic course that corresponds to one or more specific pollen seasons.",
"   </p>",
"   <p>",
"    Seasonal allergens include tree pollens in the spring, grass pollens in the summer, and weed pollens in the late summer and fall, although there is some variation based upon geographic location (",
"    <a class=\"graphic graphic_figure graphicRef74234 \" href=\"mobipreview.htm?26/61/27615\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Perennial allergic conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perennial allergic conjunctivitis (PAC) is a mild, chronic, allergic conjunctivitis related to environmental exposure to year-round, usually indoor, allergens such as dust mites, animal danders, and molds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute allergic conjunctivitis, SAC, and PAC have different clinical courses, although their origin and pathophysiology are similar. All three types result from classic Type I IgE&ndash;mediated hypersensitivity, which is similar to the pathophysiology of other atopic diseases. Analysis of conjunctival scrapings reveals two phases of the allergic response, similar to the early and late phases of cutaneous, nasal, and pulmonary responses to allergen.",
"   </p>",
"   <p>",
"    The immediate response to allergens is mediated predominantly by mast cells, which are present in high concentrations in the conjunctiva, and increase further in patients with allergic conjunctivitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/10\">",
"     10",
"    </a>",
"    ]. Mast cells become activated when allergen-IgE crosslinking occurs, and chemical mediators are released by exocytosis. Histamine is the main mediator of the early response. It causes vasodilatation, vasopermeability, and itching. Both H1-receptors and H2-receptors play a role in ocular allergy. Elevated levels of histamine in tears have been observed in patients with SAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mast cells also release a variety of cytokines and chemokines, resulting in the influx of other inflammatory cells and continued inflammation, which represents the late phase of the allergic reaction. Eosinophils, basophils, and neutrophils appear 6 to 10 hours after allergen challenge, followed by lymphocytes and monocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. Eosinophils produce and release leukotriene C4, eosinophilic peroxidase, eosinophilic cationic protein, and histamine into the tear fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More detailed discussions of the cellular and molecular mechanisms of atopy are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31848?source=see_link\">",
"     \"The biology of IgE\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of allergic conjunctivitis is made clinically based on suggestive signs and symptoms. Laboratory tests are generally not needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of these findings includes infectious conjunctivitis, blepharitis, and dry eye. There are no universally specific signs or symptoms that differentiate these conditions in all cases, and more than one condition can coexist in the same patient. However, there are several features that can help distinguish allergic conjunctivitis from other disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergic conditions are often accompanied by significant itch, whereas this is not very common in infection.",
"     </li>",
"     <li>",
"      Allergic conjunctivitis principally affects the conjunctiva, whereas the principal target tissue in dry eye is the cornea. Corneal involvement is characterized by vital dye uptake. This test can readily be performed by an ophthalmologist. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25784?source=see_link\">",
"       \"Dry eyes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differential diagnosis of conjunctivitis is presented more fully elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20760?source=see_link\">",
"     \"Conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GENERAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;General measures that are helpful for patients with allergic conjunctivitis include instructions not to rub the eyes, treatment of concomitant dry eye, advice about allergen avoidance, and referral to an allergy or ophthalmology specialist if indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25784?source=see_link\">",
"     \"Dry eyes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Basic eye care",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all types of allergic conjunctivitis, patients should not rub their eyes because that can cause mechanical mast cell degranulation and worsening of symptoms. Frequent use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    throughout the day can also help to dilute and remove allergens. During acute episodes of itching, patients should be instructed to use topical antihistamines, frequent artificial tears, and cool compresses.",
"   </p>",
"   <p>",
"    Avoidance or reduction of contact with known allergens and appropriate management of environmental exposure are key to effective management of allergic conjunctivitis, especially in more severe cases. This includes significant reduction (or even complete avoidance) of contact lens use, given the propensity of allergens to adhere to contact lens surfaces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment of dry eyes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tear film insufficiency is an extremely common disorder, particularly among women and the elderly, which can coexist with allergic conjunctivitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/17\">",
"     17",
"    </a>",
"    ]. Tear film insufficiency frequently worsens allergic conjunctivitis through two mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Concentration of allergen is higher with tear film insufficiency",
"     </li>",
"     <li>",
"      Ability to rinse away the offending allergen is diminished",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients with allergic conjunctivitis who do not respond fully to the standard treatments outlined below should be evaluated for concomitant dry eyes by an eye care practitioner. Simply asking whether the eyes feel dry may not adequately detect affected patients, as those with mild to moderate dry eyes may not report symptoms.",
"   </p>",
"   <p>",
"    Signs of tear film insufficiency include superficial punctate-keratopathy, reduced tear break-up time, and decreased production of tears as measured by the Schirmer's test. Various medications, such as oral antihistamines, can exacerbate tear film insufficiency because they cause a decrease in tear production due to their anticholinergic effects.",
"   </p>",
"   <p>",
"    Patients with both dry eyes and allergic conjunctivitis respond to frequent use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    throughout the day. In order to avoid washing one drop out with application of the other, patients should space drops by 5 to 10 minutes, during which the negative pressure generated by blinking will remove all excess medication from the ocular surface. In some, punctal plugs are also very helpful and can be placed quickly and painlessly in the ophthalmologist's office.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4438468\">",
"    <span class=\"h2\">",
"     Combining treatments for different conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical medications can wash out of the ocular surface quickly upon blinking. Two strategies can decrease medication washout. First, it is advisable to space multiple eye drops by a few minutes (three to five minutes if possible), so that instillation of a second drop does not wash out the previous drug instilled. Second, closure of the eyelids after drug instillation helps absorption into ocular tissues. These recommendations need to be balanced with the lifestyle limitations and realities faced by the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Allergen avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoidance of the allergen is the primary therapy whenever possible. Preventive steps to reduce symptoms of SAC include limiting outdoor exposure, use of air conditioning, and keeping car and home windows closed during the peak seasons.",
"   </p>",
"   <p>",
"    For patients with PAC, prevention includes replacement of old pillows and mattresses, effective covers for pillows and mattresses, frequent washing of beddings, reducing humidity, and frequent vacuuming and dusting of the home. Additionally, other reservoirs of dust should be removed such as old carpets, old furniture, and old curtains or drapes. When the allergen is animal dander, the animal may need to be removed from the home, and old carpets, furniture, and curtains should be removed or cleaned frequently. The avoidance and reduction of indoor allergen levels are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34569?source=see_link\">",
"     \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Avoidance measures for indoor allergens can be expensive, and some clinicians prefer to pursue testing for specific IgE by an allergist prior to recommending involved allergen remediation measures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Allergy evaluation and immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to an allergy specialist for possible skin testing is indicated for severe allergic conjunctivitis that is not controlled adequately by standard therapy. Referral is also appropriate for the management of concurrent allergic rhinitis, asthma, or systemic allergic symptoms, regardless of severity.",
"   </p>",
"   <p>",
"    Allergy specialists can assist the patient in correct identification and avoidance of the culprit allergens, help guide pharmacotherapy, and offer allergen immunotherapy to appropriate patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39049?source=see_link&amp;anchor=H9#H9\">",
"     \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\", section on 'Allergic rhinitis and conjunctivitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     STEPWISE APPROACH TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A stepwise approach to the treatment of allergic conjunctivitis is proposed, based upon the frequency and severity of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Acute allergic conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of acute allergic conjunctivitis are self-limited (usually lasting less than 24 hours) and do not require long-term treatment, as mentioned previously. The mainstay of management is future avoidance of the allergen.",
"   </p>",
"   <p>",
"    If pharmacologic treatment is needed, then several options exist:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Over-the-counter topical",
"      <span class=\"nowrap\">",
"       antihistamine/vasoconstrictors",
"      </span>",
"      are usually sufficient in treating symptoms of short-duration (eg, less than two weeks). The vasoconstrictor component activates the post-junctional, alpha-adrenergic receptors found in blood vessels, causing vasoconstriction and decreased conjunctival edema. Examples of topical",
"      <span class=\"nowrap\">",
"       antihistamine/vasoconstrictor",
"      </span>",
"      drugs include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/24/33152?source=see_link\">",
"       naphazoline",
"      </a>",
"      <span class=\"nowrap\">",
"       HCl/pheniramine",
"      </span>",
"      maleate (available as Naphcon-A, Opcon-A, Visine-A, and others). Dosing is up to four times daily during acute symptoms. Regular use for longer than two weeks can lead to rebound hyperemia and patients should be advised that these products are intended for short term or episodic use only [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral, nonsedating, over-the-counter or prescription antihistamines are another option for occasional acute allergic conjunctivitis. However, topical agents are faster-acting and less likely to cause systemic side effects, and are therefore preferred when ocular symptoms are the main presenting problem.",
"     </li>",
"     <li>",
"      Single agent topical products (ie, decongestants or antihistamines only) are also widely available without a prescription, although the combination of an antihistamine and a vasoconstrictor works better than either agent alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Frequent episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;For frequent attacks of acute allergic conjunctivitis (ie, occurring more than two days per month), a topical medication with both antihistamine and mast cell stabilizing properties is a better choice than a preparation containing a vasoconstrictor. Full efficacy of prophylactic therapy with these agents can be assessed after at least two weeks of therapy.",
"   </p>",
"   <p>",
"    These agents have two main actions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As mast cell stabilizers, they inhibit mast cell degranulation, which is the first step in the allergic cascade. They also inhibit leukocyte activity and dampen mediator release from mast cells, basophils, eosinophils, and neutrophils [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As antihistamines, they competitively and reversibly block histamine receptors in the conjunctiva and eyelids, thus blocking the actions of the primary mast cell-derived mediator [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/21\">",
"       21",
"      </a>",
"      ]. This also helps reduce the late phase of the allergic response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/25/33168?source=see_link\">",
"     Olopatadine",
"    </a>",
"    was the first drug to receive approval as a combination antihistamine and mast cell stabilizer. It has been shown in vitro to inhibit histamine, tryptase, and PGD2 release from mast cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/22\">",
"     22",
"    </a>",
"    ]. The H1-receptor selectivity is superior to that of other antihistamines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/23\">",
"     23",
"    </a>",
"    ]. Common side effects include stinging upon instillation and headache.",
"   </p>",
"   <p>",
"    Other agents in this class include, but are not limited to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/24/38274?source=see_link\">",
"     alcaftadine",
"    </a>",
"    (Lastacaft),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    HCl (Optivar),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    (Alocril),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/60/16323?source=see_link\">",
"     epinastine",
"    </a>",
"    (Elestat), pemirolast potassium (Alamast), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33024?source=see_link\">",
"     ketotifen",
"    </a>",
"    fumarate (generic, Ketotifen), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/15/7411?source=see_link\">",
"     bepotastine",
"    </a>",
"    (Bepreve). Ketotifen fumarate is available in a generic formulation and is over-the-counter, as mentioned previously. Dosing is twice per day, except for Pataday and Lastacaft, which are dosed once daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Seasonal and perennial allergic conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;SAC and PAC are more debilitating than acute allergic conjunctivitis and frequently require active treatment. The onset of SAC can often be predicted based upon the patient's experience in past seasons. Treatment should be initiated at least two to four weeks before the onset of symptoms whenever possible to optimize effectiveness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Preferred agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical antihistamines with mast cell stabilizing properties (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/25/33168?source=see_link\">",
"     olopatadine",
"    </a>",
"    (Patanol, Pataday),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    HCl (Optivar),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/60/16323?source=see_link\">",
"     epinastine",
"    </a>",
"    (Elestat), pemirolast potassium (Alamast), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33024?source=see_link\">",
"     ketotifen",
"    </a>",
"    fumarate (generic, Ketotifen)) are the drugs of choice in treating SAC and PAC, since they address both the acute and more chronic aspects of these conditions. These medications were discussed previously. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Frequent episodes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other useful agents include topical mast cell stabilizers and oral antihistamines. However, each of these options presents some limitations compared to combination topical mast cell",
"    <span class=\"nowrap\">",
"     stabilizer/antihistamine",
"    </span>",
"    medications, as reviewed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mast cell stabilizers",
"      </strong>",
"      - Available agents include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37712?source=see_link\">",
"       cromolyn sodium",
"      </a>",
"      (generic, Opticrom) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5555?source=see_link\">",
"       lodoxamide tromethamine",
"      </a>",
"      (Alomide). The onset of action is 5 to 14 days after therapy has been initiated, and therefore these medicines are NOT useful for acute symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/24\">",
"       24",
"      </a>",
"      ]. In addition, dosing of mast cell stabilizers is four times daily, compared to twice daily for most agents with combined actions. These features may limit patient compliance.",
"      <br/>",
"      <br/>",
"      One randomized study compared the use of cromolyn sodium (4 percent, four times daily) for two weeks prior to allergen challenge to a single drop of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33024?source=see_link\">",
"       ketotifen",
"      </a>",
"      fumarate (0.025 percent) given just before allergen challenge. The single drop of ketotifen was superior in controlling itching and redness at 15 minutes and 4 hours after challenge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      An analysis comparing the economic cost to the United Kingdom's National Health Service of prescribing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/25/33168?source=see_link\">",
"       olopatadine",
"      </a>",
"      or cromolyn concluded that the more expensive olopatadine resulted in sufficiently fewer return visits, that it was the more cost effective option [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Nonsedating oral antihistamines",
"      </strong>",
"      - Nonsedating oral antihistamines include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"       fexofenadine",
"      </a>",
"      (generic, Allegra),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      (generic, Claritin),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12934?source=see_link\">",
"       desloratadine",
"      </a>",
"      (Clarinex),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      (Zyrtec), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/45/44757?source=see_link\">",
"       levocetirizine",
"      </a>",
"      (Xyzal).",
"      <br/>",
"      <br/>",
"      Several of these agents have demonstrated efficacy in the treatment of allergic conjunctivitis, compared to placebo, in studies of varying rigor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]. Oral administration of antihistamines results in peak serum levels in 30 minutes to 3 hours, depending on the specific drug. Full effects are seen after several days of use. Thus, these agents have a slower onset of action compared to topical agents, although this is not relevant if they are taken prophylactically.",
"      <br/>",
"      <br/>",
"      As mentioned previously, oral antihistamine use may be associated with drying of mucosal membranes and decreased tear production in some patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/30\">",
"       30",
"      </a>",
"      ], especially those with concomitant dry eye [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/30\">",
"       30",
"      </a>",
"      ]. This side effect can usually be countered with the liberal application of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      . Cetirizine causes sedation in a subset of patients, despite its categorization as nonsedating.",
"      <br/>",
"      <br/>",
"      Oral loratadine and fexofenadine were less effective than topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/25/33168?source=see_link\">",
"       olopatadine",
"      </a>",
"      in randomized trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. Similarly, oral desloratadine was less effective than topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33024?source=see_link\">",
"       ketotifen",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Nonsteroidal antiinflammatory drugs",
"      </strong>",
"      - NSAIDs block the action of cyclooxygenase and thus inhibit the conversion of arachidonic acid to prostaglandins and thromboxanes. In practical terms, however, NSAIDs are not considered to be as effective as other medical therapy in treating allergic ocular disease. As an example,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/62/35808?source=see_link\">",
"       ketorolac",
"      </a>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/29/43475?source=see_link\">",
"       tromethamine",
"      </a>",
"      was more effective than placebo in reducing the symptoms of acute allergic conjunctivitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/34\">",
"       34",
"      </a>",
"      ]. However, it was less effective than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/25/33168?source=see_link\">",
"       olopatadine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/20/323?source=see_link\">",
"       emedastine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. Thus, NSAIDs are not recommended for the treatment of allergic conjunctivitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Patients with concomitant rhinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with concomitant allergic rhinitis, a topical agent that has both mast cell stabilizing and antihistamine properties can be combined with either an intranasal glucocorticoid or an oral antihistamine.",
"   </p>",
"   <p>",
"    In a randomized study,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/25/33168?source=see_link\">",
"     olopatadine",
"    </a>",
"    combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    propionate nasal spray was superior to olopatadine combined with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"     fexofenadine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/37\">",
"     37",
"    </a>",
"    ]. The relative merits of intranasal steroids and oral antihistamines in the treatment of allergic rhinitis are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37834?source=see_link\">",
"     \"Pharmacotherapy of allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Refractory symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of patients will not achieve control of their allergic conjunctivitis despite the above therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Ophthalmology referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to an ophthalmologist is highly recommended for patients who do not respond to two or three weeks of consistent therapy with an",
"    <span class=\"nowrap\">",
"     antihistamine/mast",
"    </span>",
"    cell stabilizer agent.",
"   </p>",
"   <p>",
"    Topical glucocorticoid preparations may be considered in patients with refractory symptoms. Glucocorticoids suppress the late phase reaction in both experimental and clinical settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/38\">",
"     38",
"    </a>",
"    ]. Glucocorticoids in part inhibit the inflammatory cascade by inhibiting phospholipase A2, and consequently, they reduce the formation of lipid-derived mediators from arachidonic acid. This prevents leukocyte migration, hydrolytic enzyme release, fibroblast growth, and changes in vascular permeability.",
"   </p>",
"   <p>",
"    Serious ocular side effects are well known with topical glucocorticoids use, and they should",
"    <strong>",
"     only be used",
"    </strong>",
"    for short \"pulse therapy\" among patients in whom antihistamines and mast cell stabilizers provide inadequate therapy. Ocular side effects from glucocorticoid use can be vision-threatening, and include cataract formation, elevated intraocular pressure (IOP), glaucoma, and secondary infections. Consequently, steroids should only be used with the supervision of an ophthalmologist, and the patient should know that blindness is a risk of",
"    <strong>",
"     unsupervised",
"    </strong>",
"    glucocorticoid therapy.",
"   </p>",
"   <p>",
"    Among all topical steroids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    acetate (1 percent) has the greatest risk of raising IOP, with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    phosphate (0.1 percent) having the next greatest risk. By comparison, \"soft\" steroids are a group of topical glucocorticoids that have a greatly reduced risk of causing increased IOP, since they are formulated such that they undergo rapid inactivation upon penetration of the cornea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34856/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    \"Soft\" steroids include Pred Mild (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ), FML (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/49/41748?source=see_link\">",
"     fluorometholone",
"    </a>",
"    ), HMS (medrysone), Lotemax (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/48/39684?source=see_link\">",
"     loteprednol",
"    </a>",
"    ), and Vexol (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/13/20691?source=see_link\">",
"     rimexolone",
"    </a>",
"    ). These agents are administered two to four times per day for approximately two weeks. Use of topical soft steroids for greater than six weeks is associated with a significantly increased risk of complications. However, a two-week course of topical \"soft\" steroids can help slow the immune response so that the mast cell stabilizers, antihistamines, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    have a greater chance to work.",
"   </p>",
"   <p>",
"    If control is not obtained with topical steroids after two to three weeks of therapy, the patient should be referred to an allergist for consideration of immunotherapy. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Allergy evaluation and immunotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/6/26721?source=see_link\">",
"       \"Patient information: Conjunctivitis (pinkeye) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/27/5553?source=see_link\">",
"       \"Patient information: Allergic conjunctivitis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/51/20274?source=see_link\">",
"       \"Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The signs and symptoms of allergic conjunctivitis include itching, tearing, conjunctival edema, hyperemia, watery discharge, burning, and photophobia (",
"      <a class=\"graphic graphic_picture graphicRef57240 \" href=\"mobipreview.htm?14/20/14670\">",
"       picture 1",
"      </a>",
"      ). Eyelid edema is also common. Symptoms are usually bilateral, although one eye can be affected more than the other. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Allergic conjunctivitis can be subdivided into acute allergic conjunctivitis, seasonal allergic conjunctivitis (SAC), and perennial allergic conjunctivitis (PAC):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acute allergic conjunctivitis is a sudden-onset hypersensitivity reaction caused by an isolated environmental exposure, and resolves promptly with removal of the allergen.",
"     </li>",
"     <li>",
"      SAC typically has a more gradual onset and a course that corresponds to one or more specific pollen seasons (",
"      <a class=\"graphic graphic_figure graphicRef74234 \" href=\"mobipreview.htm?26/61/27615\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      PAC is a mild, chronic conjunctivitis related to environmental exposure to year-round, usually indoor, allergens. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Types of allergic conjunctivitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of allergic conjunctivitis is made clinically based upon suggestive signs and symptoms. The presence of itching is particularly helpful in distinguishing allergic conjunctivitis from other conditions. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;General management includes instructions not to rub the eyes, advice about allergen avoidance, detection and treatment of concomitant dry eye, and referral to an allergy or ophthalmology specialist if indicated. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'General management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Acute intermittent symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Separation from the source of allergen is the primary treatment for this self-limited condition.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients requiring additional therapy to reduce symptoms, we suggest short-term administration of over-the-counter topical",
"      <span class=\"nowrap\">",
"       antihistamine/vasoconstrictor",
"      </span>",
"      agents in preference to other agents (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The vasoconstrictor component reduces redness and conjunctival edema, but can cause rebound hyperemia beyond two weeks of use. Examples include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/24/33152?source=see_link\">",
"       naphazoline",
"      </a>",
"      <span class=\"nowrap\">",
"       HCl/pheniramine",
"      </span>",
"      maleate (Naphcon-A, Opcon-A, Visine-A, and others). Dosing is up to four times daily. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Acute allergic conjunctivitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with frequent episodes (ie, occurring more than two days per month), we suggest administering a topical agent with both antihistamine and mast cell stabilizing properties (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Examples include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/25/33168?source=see_link\">",
"       olopatadine",
"      </a>",
"      (Patanol or Pataday),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/15/33008?source=see_link\">",
"       azelastine",
"      </a>",
"      HCl (Optivar),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/43/691?source=see_link\">",
"       nedocromil",
"      </a>",
"      (Alocril),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/60/16323?source=see_link\">",
"       epinastine",
"      </a>",
"      (Elestat), pemirolast potassium (Alamast), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33024?source=see_link\">",
"       ketotifen",
"      </a>",
"      fumarate (generic, Ketotifen). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Frequent episodes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Seasonal and perennial symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred approach for SAC and PAC depends, in part, upon the presence of coexistent allergic rhinitis or dry eye.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with",
"      <span class=\"nowrap\">",
"       SAC/PAC",
"      </span>",
"      without significant nasal symptoms, we recommend a topical",
"      <span class=\"nowrap\">",
"       antihistamine/mast",
"      </span>",
"      cell stabilizer (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients who dislike eye drops, a nonsedating oral antihistamine is a less-effective alternative. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Seasonal and perennial allergic conjunctivitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with concomitant allergic rhinitis, we suggest a topical",
"      <span class=\"nowrap\">",
"       antihistamine/mast",
"      </span>",
"      cell stabilizer in combination with an intranasal glucocorticoid spray, in preference to other options (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The combination of a nonsedating oral antihistamine and a topical",
"      <span class=\"nowrap\">",
"       antihistamine/mast",
"      </span>",
"      cell stabilizer, although less effective, may be preferred by some patients. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Patients with concomitant rhinitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who also have dry eyes, we suggest adding liberal use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      throughout the day (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Oral antihistamines can worsen dry eye symptoms and should be avoided. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment of dry eyes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest subcutaneous allergen immunotherapy for patients who wish to minimize use of medications or prefer this mode of therapy for other reasons (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Immunotherapy is effective for allergic rhinoconjunctivitis, although it has not been extensively studied for the treatment of isolated allergic conjunctivitis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Allergy evaluation and immunotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Severe and refractory symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe ocular symptoms that persist despite at least three weeks of",
"    <span class=\"nowrap\">",
"     antihistamines/mast",
"    </span>",
"    cell stabilizer therapy should be referred to an ophthalmologist for confirmation of the diagnosis and further management. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Ophthalmology referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with refractory symptoms may benefit from the administration of topical glucocorticoids, although these agents should",
"      <strong>",
"       only",
"      </strong>",
"      be used for short \"pulse therapy\", and",
"      <strong>",
"       always",
"      </strong>",
"      under the supervision of an ophthalmologist. Side effects include cataract formation, elevated intraocular pressure, glaucoma, and secondary infections. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Refractory symptoms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/1\">",
"      Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol 2010; 126:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/2\">",
"      Wang HY, Pizzichini MM, Becker AB, et al. Disparate geographic prevalences of asthma, allergic rhinoconjunctivitis and atopic eczema among adolescents in five Canadian cities. Pediatr Allergy Immunol 2010; 21:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/3\">",
"      Kusunoki T, Morimoto T, Nishikomori R, et al. Changing prevalence and severity of childhood allergic diseases in kyoto, Japan, from 1996 to 2006. Allergol Int 2009; 58:543.",
"     </a>",
"    </li>",
"    <li>",
"     Doshnik PC, Ehlers WH. Clinical immunologic diseases: Ocular allergy. In: The cornea: Scientific foundation and clinical practice, 3rd ed, Smolin G, Thoft RA (Eds), Little Brown, Boston 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/5\">",
"      Abelson MB, Udell IJ, Weston JH. Conjunctival eosinophils in compound 48/80 rabbit model. Arch Ophthalmol 1983; 101:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/6\">",
"      Brauninger GE, Centifanto YM. Immunoglobulin E in human tears. Am J Ophthalmol 1971; 72:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/7\">",
"      Insler MS, Lim JM, Queng JT, et al. Tear and serum IgE concentrations by Tandem-R IgE immunoradiometric assay in allergic patients. Ophthalmology 1987; 94:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/8\">",
"      Rodier F, Gautrin D, Ghezzo H, Malo JL. Incidence of occupational rhinoconjunctivitis and risk factors in animal-health apprentices. J Allergy Clin Immunol 2003; 112:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/9\">",
"      Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005; 115:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/10\">",
"      Tsubota K, Takamura E, Hasegawa T, Kobayashi T. Detection by brush cytology of mast cells and eosinophils in allergic and vernal conjunctivitis. Cornea 1991; 10:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/11\">",
"      Ehlers WH, Donshik PC. Allergic ocular disorders: a spectrum of diseases. CLAO J 1992; 18:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/12\">",
"      Bonini S, Bonini S, Berruto A, et al. Conjunctival provocation test as a model for the study of allergy and inflammation in humans. Int Arch Allergy Appl Immunol 1989; 88:144.",
"     </a>",
"    </li>",
"    <li>",
"     Cohan VL, Massey WA, Gittlin SD, et al. The heterogeneity of human histamine containing cells. In: Mast cell and basophil differentiation and function in health and disease, Galli SJ, Austen KF (Eds), Raven Press, New York 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/14\">",
"      Bonini S, Centofanti M, Schiavone M, et al. The pattern of the ocular late phase reaction induced by allergen challenge in hay fever conjunctivitis. Ocul Immunol Inflamm 1994; 2:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/15\">",
"      Abelson MB, Madiwale N, Weston JH. Conjunctival eosinophils in allergic ocular disease. Arch Ophthalmol 1983; 101:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/16\">",
"      Bonini S, Centofanti M, Schiavone M. Passive transfer of the ocular late-phase reaction. Ocul Immunol Inflamm 1993; 4:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/17\">",
"      Lobefalo L, D'Antonio E, Colangelo L, et al. Dry eye in allergic conjunctivitis: role of inflammatory infiltrate. Int J Immunopathol Pharmacol 1999; 12:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/18\">",
"      Spector SL, Raizman MB. Conjunctivitis medicamentosa. J Allergy Clin Immunol 1994; 94:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/19\">",
"      Abelson MB, Allansmith MR, Friedlaender MH. Effects of topically applied occular decongestant and antihistamine. Am J Ophthalmol 1980; 90:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/20\">",
"      Berdy GJ, Smith LM, George MA. The effects of disodium cromoglycate in the human model of acute allergic conjunctivitis. Invest Ophthalmol Vis Sci 1989; 30 suppl:503.",
"     </a>",
"    </li>",
"    <li>",
"     Stiehm ER, Ochs HD, Winkelstein JA. Immunodeficiency disorders: General considerations. In: Immunologic disorders in infants and children, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier Saunders, Philadelphia 2004. p.423.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/22\">",
"      Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther 1996; 12:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/23\">",
"      Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther 1996; 12:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/24\">",
"      Nizami RM. Treatment of ragweed allergic conjunctivitis with 2% cromolyn solution in unit doses. Ann Allergy 1981; 47:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/25\">",
"      Greiner JV, Michaelson C, McWhirter CL, Shams NB. Single dose of ketotifen fumarate .025% vs 2 weeks of cromolyn sodium 4% for allergic conjunctivitis. Adv Ther 2002; 19:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/26\">",
"      Guest JF, Clegg JP, Smith AF. Health economic impact of olopatadine compared to branded and generic sodium cromoglycate in the treatment of seasonal allergic conjunctivitis in the UK. Curr Med Res Opin 2006; 22:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/27\">",
"      Schoeneich M, P&eacute;coud AR. Effect of cetirizine in a conjunctival provocation test with allergens. Clin Exp Allergy 1990; 20:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/28\">",
"      Bronsky EA, Falliers CJ, Kaiser HB, et al. Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies. Allergy Asthma Proc 1998; 19:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/29\">",
"      Ciprandi G, Buscaglia S, Pesce GP, et al. Protective effect of loratadine on specific conjunctival provocation test. Int Arch Allergy Appl Immunol 1991; 96:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/30\">",
"      Ousler GW 3rd, Workman DA, Torkildsen GL. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clin Ther 2007; 29:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/31\">",
"      Abelson MB, Welch DL. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol Scand Suppl 2000; :60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/32\">",
"      Spangler DL, Abelson MB, Ober A, Gotnes PJ. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Clin Ther 2003; 25:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/33\">",
"      Crampton HJ. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial. Clin Ther 2003; 25:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/34\">",
"      Tinkelman DG, Rupp G, Kaufman H, et al. Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993; 38 Suppl:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/35\">",
"      Yaylali V, Demirlenk I, Tatlipinar S, et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scand 2003; 81:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/36\">",
"      Discepola M, Deschenes J, Abelson M. Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis. Acta Ophthalmol Scand Suppl 1999; :43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/37\">",
"      Lanier BQ, Abelson MB, Berger WE, et al. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge. Clin Ther 2002; 24:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/38\">",
"      Schleimer RP. Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma. Am Rev Respir Dis 1990; 141:S59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34856/abstract/39\">",
"      Druzgala P, Wu WM, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res 1991; 10:933.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5547 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-FA0D210239-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_2_34856=[""].join("\n");
var outline_f34_2_34856=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TYPES OF ALLERGIC CONJUNCTIVITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Acute allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Seasonal allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Perennial allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GENERAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Basic eye care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment of dry eyes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4438468\">",
"      Combining treatments for different conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Allergen avoidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Allergy evaluation and immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      STEPWISE APPROACH TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Acute allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Frequent episodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Seasonal and perennial allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Preferred agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Patients with concomitant rhinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Refractory symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Ophthalmology referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Acute intermittent symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Seasonal and perennial symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Severe and refractory symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5547\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5547|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/61/27615\" title=\"figure 1\">",
"      Peak pollen periods US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5547|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/20/14670\" title=\"picture 1\">",
"      Acute seasonal conjunctivitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34569?source=related_link\">",
"      Allergen avoidance in the treatment of asthma and allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20760?source=related_link\">",
"      Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25784?source=related_link\">",
"      Dry eyes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/27/5553?source=related_link\">",
"      Patient information: Allergic conjunctivitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/51/20274?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/6/26721?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39049?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31848?source=related_link\">",
"      The biology of IgE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_2_34857="Crystal-induced acute kidney injury (acute renal failure)";
var content_f34_2_34857=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Crystal-induced acute kidney injury (acute renal failure)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/2/34857/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/2/34857/contributors\">",
"     Mark A Perazella, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/2/34857/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/2/34857/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/2/34857/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/2/34857/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/2/34857/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4164196\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crystal-induced acute kidney injury (AKI) is caused by the intratubular precipitation of crystals which results in obstruction. Crystal-induced AKI most commonly occurs as a result of acute uric acid nephropathy, and following the administration of drugs or toxins that are poorly soluble or have metabolites that are poorly soluble in urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Other drugs or medications may be metabolized to insoluble products such as oxalate (ethylene glycol, vitamin C), which are associated with precipitation of calcium oxalate crystals within tubular lumens and kidney injury.",
"   </p>",
"   <p>",
"    This topic review discusses drug-related crystal induced AKI. Uric acid nephropathy and acute phosphate nephropathy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27541?source=see_link\">",
"     \"Uric acid renal diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7032?source=see_link\">",
"     \"Acute phosphate nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4164203\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple drugs and toxins cause intratubular crystal-induced obstruction. Common agents include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"     </li>",
"     <li>",
"      Sulfonamide antibiotics",
"     </li>",
"     <li>",
"      Ethylene glycol",
"     </li>",
"     <li>",
"      Megadose vitamin C",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"     </li>",
"     <li>",
"      Protease inhibitors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other agents that have been described in case reports to cause crystal-induced AKI include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    , oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    purgatives, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4164210\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with drug-related crystal-induced AKI are usually asymptomatic and kidney injury is detected by an increased serum creatinine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/3\">",
"     3",
"    </a>",
"    ]. Occasionally patients present within one to seven days after initiation of the offending drug with renal colic symptoms such as flank or abdominal pain, nausea or vomiting.",
"   </p>",
"   <p>",
"    Urinalysis often reveals hematuria, pyuria, and crystalluria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Significant proteinuria (ie, &gt;500",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is not commonly observed unless the patient has underlying proteinuric kidney disease and subsequently develops crystal-induced AKI.",
"   </p>",
"   <p>",
"    The diagnosis is suggested by the appearance of crystals in the urine, the morphology of which depends upon the specific causative drug. (See appropriate sections below). However crystalluria may also be observed in patients who have no evidence of AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Definitive diagnosis is obtained by examination of histology obtained by biopsy. In general however, a biopsy is not indicated in patients who present with AKI in the setting of starting a drug that is known to cause crystal-induced AKI, unless atypical features (such as significant proteinuria in a patient who does not have underlying proteinuric kidney disease) are present.",
"   </p>",
"   <p>",
"    The differential diagnosis for crystal-induced AKI is AKI from any cause and, among patients who present with hematuria and even modest proteinuria, glomerulonephritis. The diagnostic approaches to these disorders are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link\">",
"     \"Differential diagnosis and evaluation of glomerular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Crystal-induced AKI is generally reversed following discontinuation of the drug, although temporary dialysis may be necessary in some cases, and chronic kidney disease may be a long-term consequence of crystal-induced AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4164217\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for crystal-induced kidney injury include true and \"effective\" intravascular volume depletion, underlying kidney or liver disease, and metabolic perturbations that change urinary pH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ]. The effect of urine pH on crystal formation varies depending upon the specific causative agents. As an example, whereas sulfonamides tend to form crystals in acidic urine, protease inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    form crystals in alkaline urine.",
"   </p>",
"   <p>",
"    Excessive drug dosing for a given glomerular filtration rate may contribute to the risk of kidney injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101517554\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The correction of volume depletion is critical to prevent crystal-induced AKI among patients at risk. Therapy of established crystal-induced AKI is supportive and consists of volume repletion, usually with isotonic saline, and administration of a loop diuretic in an attempt to wash out the obstructing crystals. The use of loop diuretics is of theoretical benefit only and its efficacy has not been shown. Despite the absence of proven efficacy, we generally administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    . Fluid loss induced by the diuretic must be replaced to prevent volume depletion and a late slowing of flow within the tubules.",
"    <br/>",
"    <br/>",
"    In addition to volume repletion and loop diuretics, among patients with crystal-induced AKI due specific medications (as for example, sulfonamide antibiotics and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ), adjusting the urine pH to achieve better solubility of the crystal may be of benefit. These issues and specific treatments, where indicated, are discussed below. (See",
"    <a class=\"local\" href=\"#H4164288\">",
"     'Sulfonamide antibiotics'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H4164341\">",
"     'Methotrexate'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4164281\">",
"    <span class=\"h1\">",
"     SPECIFIC AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101518418\">",
"    <span class=\"h2\">",
"     Acyclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    is rapidly excreted in the urine (being both filtered and secreted) and has a relatively low solubility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, bolus intravenous therapy, especially if the patient is volume depleted, may lead to the deposition of acyclovir crystals in the tubules, resulting in intratubular obstruction and foci of interstitial inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    , another antiviral agent that is structurally related to acyclovir and is also excreted in the urine, appears to be associated with a much lower risk of crystal-induced AKI compared with acyclovir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    Renal function in affected patients typically begins to deteriorate within 24 to 48 hours after therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is initiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Patients may complain of nausea and flank or abdominal pain at this time, presumably induced by the urinary tract obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/4\">",
"     4",
"    </a>",
"    ]. In some cases, birefringent needle-shaped acyclovir crystals, occasionally engulfed by white cells, can be seen in the urine, particularly under polarized light.",
"   </p>",
"   <p>",
"    The decline in kidney function is usually mild but occasionally may be severe, with marked increases in the plasma creatinine concentration in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. However, complete recovery typically occurs within four to nine days after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is discontinued.",
"   </p>",
"   <p>",
"    It is likely that most cases of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    nephrotoxicity, which is likely due in part to direct tubular toxicity and in part to luminal crystal-associated obstruction, can be prevented by prior volume repletion (with the urine output maintained above 75",
"    <span class=\"nowrap\">",
"     mL/h)",
"    </span>",
"    and slow intravenous drug infusion over one to two hours. We generally administer intravenous isotonic saline at a rate of 125",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    starting at least one hour prior to the administration of acyclovir and continuing for six hours after the acyclovir infusion is finished. Patients who develop AKI can usually be safely rechallenged (if necessary) by limiting the dose to 250",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    or less [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/4\">",
"     4",
"    </a>",
"    ]. Oral therapy is usually well tolerated, presumably due to a less rapid rate of acyclovir excretion. Rarely, AKI can develop with oral acyclovir in patients with underlying kidney disease (and excessive dosing) and severe volume depletion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy of established renal failure is supportive and consists of volume repletion, usually with isotonic saline and administration of a loop diuretic in an attempt to wash out the obstructing crystals. As noted above, although the use of loop diuretics is of theoretical benefit only and its efficacy has not been shown, we generally administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    . Fluid loss induced by the diuretic must be replaced to prevent volume depletion and a late slowing of flow within the tubules. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=see_link\">",
"     \"Maintenance and replacement fluid therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although hemodialysis may remove substantial amounts of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/7\">",
"     7",
"    </a>",
"    ], it has not been shown to reverse or limit the duration of acyclovir-induced AKI and is not indicated for this purpose. However, neurotoxicity may develop in patients who develop severe acyclovir-induced AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/10-12\">",
"     10-12",
"    </a>",
"    ], and in this setting hemodialysis may be indicated in order to remove the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, hemodialysis may be required to correct the metabolic sequelae of AKI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4164288\">",
"    <span class=\"h2\">",
"     Sulfonamide antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some sulfonamide antibiotics are relatively insoluble in acid urine, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    and sulfamethoxazole which are used in high doses to treat toxoplasmosis and Pneumocystis carinii infection in immunocompromised patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/4,13-15\">",
"     4,13-15",
"    </a>",
"    ]. Up to 29 percent of patients treated with sulfadiazine are at risk to develop AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/1,13-16\">",
"     1,13-16",
"    </a>",
"    ], because this drug is highly insoluble in urine with a pH of 5.5 or less [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/16\">",
"     16",
"    </a>",
"    ]. Intrarenal sulfadiazine precipitation may also result in nephrolithiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/15\">",
"     15",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    The risk of crystal precipitation increases with doses of sulfadiazine of 4 to 6",
"    <span class=\"nowrap\">",
"     g/day;",
"    </span>",
"    and of sulfamethoxazole of 50 to 100",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Alkalinization of the urine to a pH above 7.15 increases sulfadiazine solubility more than 20-fold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/4,13\">",
"     4,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sulfonamide crystals can assume many shapes in part dependent upon the specific sulfonamide present. The most common morphology includes needle-shaped crystals, rosettes, and those resembling shocks of wheat (",
"    <a class=\"graphic graphic_picture graphicRef56708 \" href=\"mobipreview.htm?14/33/14865\">",
"     picture 1",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/41/20118?source=see_link\">",
"     Sulfadiazine",
"    </a>",
"    sludge or small calculi in the calyces can also be detected in some cases as bilateral layered clusters of echogenic material on renal ultrasonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/4,16\">",
"     4,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intrarenal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    precipitation may be prevented by maintaining fluid intake above three liters per day, which may be administered orally or intravenously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients who are receiving sulfadiazine should be monitored by serial urinalyses for the development of crystalluria. Among patients who develop crystalluria, we administer an intravenous bicarbonate solution to alkalinize the urine to &ge;7.15 in order to prevent AKI. To patients who are euvolemic and have normal renal function and a normal serum sodium concentration, we give a solution containing 75 mEq",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    per liter of sterile water. If the patient is hypovolemic, we give an isotonic solution (containing 75 mEq sodium bicarbonate per liter of one-half isotonic saline). We generally give approximately 3 L per day (ie, infusion rate of 125",
"    <span class=\"nowrap\">",
"     mL/hour).",
"    </span>",
"   </p>",
"   <p>",
"    Patients who are receiving prophylactic intravenous bicarbonate should be closely monitored by physical exam for volume overload and by daily measurement of serum creatinine and electrolytes for development of AKI, alkalosis or other electrolyte abnormalities.",
"   </p>",
"   <p>",
"    Some patients may develop AKI despite prophylactic volume repletion and alkalinization of urine. Among such patients, AKI usually resolves when the sulfonamide is discontinued. The treatment of established AKI is supportive. Volume depletion, if present, should be treated in all patients, usually with isotonic saline. The administration of loop diuretics may assist recovery of renal function by clearing obstructive casts from tubular lumen, although there are no published data that have demonstrated a benefit of loop diuretics.",
"   </p>",
"   <p>",
"    Among patients with established AKI, a forced alkaline diuresis to a target urine pH &gt;7.15 may provide benefit by increasing the solubility of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    , although there are no published studies that show that this treatment reverses or limits the duration of established sulfonamide-associated AKI.",
"   </p>",
"   <p>",
"    In addition to a lack of clear evidence of benefit, maintaining the urine pH above 7.15 is difficult in patients with established AKI. There are also potential risks to alkalinization of the plasma, such as promoting calcium phosphate deposition (which is more likely if hyperphosphatemia is present), and inducing or worsening the manifestations of hypocalcemia by both a direct membrane effect and a reduction in ionized calcium levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/17\">",
"     17",
"    </a>",
"    ]. Manifestations of severe hypocalcemia include tetany, seizures, and cardiac arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36646?source=see_link\">",
"     \"Clinical manifestations of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these limitations, patients who are appropriately monitored may benefit from intravenous bicarbonate therapy. For patients who have a urine pH &le;7.15, we generally administer a solution (mixed by the pharmacy) containing 140 mEq of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    per liter of sterile water at a rate of 125",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    along with a loop diuretic such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    , providing patients are not oliguric, and do not have hypocalcemia or metabolic alkalosis, or an indication for acute hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=see_link&amp;anchor=H2#H2\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\", section on 'Indications for and timing of initiation of dialysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with established AKI, the bicarbonate infusion should be discontinued if the urine pH does not rise above 7.0 after twelve hours or if metabolic alkalosis or volume overload develops.",
"   </p>",
"   <p>",
"    There is no benefit to hemodialysis for the removal of sulfonamides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4164341\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 90 percent of administered",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) is normally excreted unchanged in the urine. High-dose intravenous MTX can both precipitate in the tubules and cause direct tubular injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    The risk of MTX-induced nephrotoxicity is increased with an acidic urine (since MTX is poorly soluble in an acidic urine), and with volume depletion (which decreases urine flow rate and increases the concentration of MTX in tubular fluid). In addition, the risk of MTX nephrotoxicity is higher when there is sustained elevation in the plasma MTX concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of developing AKI can be minimized by prior volume repletion (both to maintain a high urine flow and to lower the concentration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in the tubular fluid) and by alkalinization of the urine to a pH above 7.0, which can increase the solubility of methotrexate by as much as tenfold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/19\">",
"     19",
"    </a>",
"    ]. Among all patients who are receiving intravenous methotrexate, we administer an intravenous bicarbonate solution to alkalinize the urine to &ge;7.0 in order to prevent AKI. To patients who are euvolemic and have normal renal function and a normal serum sodium concentration, we give a solution containing 75 mEq",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    per liter of sterile water that is mixed by the pharmacy. If the patient is hypovolemic, we give an isotonic solution (containing 75 mEq sodium bicarbonate per liter of one-half isotonic saline). We generally give approximately 3 L per day (ie, infusion rate of 125",
"    <span class=\"nowrap\">",
"     mL/hour).",
"    </span>",
"    The bicarbonate infusion should be begun 12 hours before MTX administration and continue for 24 to 48 hours.",
"   </p>",
"   <p>",
"    The incidence of MTX-induced AKI in the era of routine intravascular volume repletion and urinary alkalinization was reported to be 1.8 percent in an analysis of data from clinical trials in osteosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MTX-induced AKI is typically nonoliguric and usually reversible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The plasma creatinine concentration usually peaks within the first week and returns well toward baseline levels within one to three weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of MTX-induced AKI is directed at volume repletion, washing out the crystals within tubular lumens via the administration of a loop diuretic, and alkalinization of urine. There are no studies that have proven a benefit of either loop diuretics or alkalinization of urine and these measures are of theoretical benefit only",
"   </p>",
"   <p>",
"    As described above, maintaining the urine pH above 7.0 is difficult in patients with AKI and associated with potential risks including calcium phosphate deposition, and inducing or worsening the manifestations of hypocalcemia by both a direct membrane effect and a reduction in ionized calcium levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4164288\">",
"     'Sulfonamide antibiotics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Despite these limitations, given the potential benefit of bicarbonate therapy, we administer a bicarbonate infusion to all patients who have",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -related AKI, providing they are not oliguric, and do not have hypocalcemia or metabolic alkalosis, or an indication for acute hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=see_link&amp;anchor=H2#H2\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\", section on 'Indications for and timing of initiation of dialysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We generally administer a solution containing 140 mEq",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    per liter of sterile water at a rate of 125",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    intravenously along with a loop diuretic such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    , providing patients are not oliguric, and do not have hypocalcemia or metabolic alkalosis, or an indication for acute hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=see_link&amp;anchor=H2#H2\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\", section on 'Indications for and timing of initiation of dialysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The bicarbonate infusion should be discontinued if the urine pH does not rise above 7.0 after twelve hours or metabolic alkalosis develops.",
"   </p>",
"   <p>",
"    AKI often results in an elevated plasma MTX concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/21\">",
"     21",
"    </a>",
"    ]. This is clinically very important since it may increase the toxicity of MTX, as decreased urinary excretion results in elevated plasma drug levels that can last for as long as two to three weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/20\">",
"     20",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     Leucovorin",
"    </a>",
"    rescue with or without thymidine is effective in this setting, although higher than usual doses are often required, and are generally based on the plasma MTX concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. Leucovorin should be continued until levels of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    fall below 0.05 micromolar. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"     Glucarpidase",
"    </a>",
"    , which rapidly metabolizes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    and chemically similar antifolates such as MTX to inactive metabolites, may prevent systemic MTX toxicity by rapidly lowering serum MTX levels that remain unacceptably high despite adequate hydration and urinary alkalinization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. In one report, for example, 65 patients with renal insufficiency",
"    <strong>",
"    </strong>",
"    and an elevated serum MTX",
"    <strong>",
"    </strong>",
"    concentration 36 to 42 hours after MTX infusion were treated with a single dose of glucarpidase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/25\">",
"     25",
"    </a>",
"    ]. Fifteen minutes following glucarpidase treatment, serum MTX levels decreased by a median of 87 percent.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"     Glucarpidase",
"    </a>",
"    also metabolizes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    , which should be continued for two days after glucarpidase administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"     Glucarpidase",
"    </a>",
"    was approved in the US in January 2012 for treatment of toxic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    plasma concentrations (&gt;1",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    [&gt;1 microM]) in patients with delayed methotrexate clearance due to impaired renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/26\">",
"     26",
"    </a>",
"    ]. Recommendations for the use of glucarpidase among patients with renal dysfunction and elevated MTX levels are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=see_link&amp;anchor=H39#H39\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\", section on 'Glucarpidase (carboxypeptidase G2)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug removal by hemodialysis, charcoal hemoperfusion, or plasma exchange is generally of limited value, since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is both protein bound (and therefore not readily dialyzable) and has a relatively large extravascular volume of distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/18,27\">",
"     18,27",
"    </a>",
"    ]. However, in one small case series, daily hemodialysis with high-flux membranes for four to six hours improved MTX clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/28\">",
"     28",
"    </a>",
"    ]. In one patient who was dialysis dependent prior to high dose methotrexate therapy, 63 percent of the drug was cleared in six hours. Analysis of seven separate MTX treatments in this patient demonstrated complete drug removal after an average of 5.6 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited data also suggest that albumin-based continuous venovenous hemodialysis (CVVHD) may provide better MTX clearance than CVVHD without albumin, presumably due to the effect of better removal of protein-bound MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4164392\">",
"    <span class=\"h2\">",
"     Protease inhibitors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4164400\">",
"    <span class=\"h3\">",
"     Indinavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     Indinavir",
"    </a>",
"    , a protease inhibitor used in the treatment of HIV infection, commonly causes asymptomatic crystalluria and may cause AKI associated with crystal deposition",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nephrolithiasis (",
"    <a class=\"graphic graphic_picture graphicRef70939 \" href=\"mobipreview.htm?21/23/21877\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/2,30-39\">",
"     2,30-39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report described 29 patients in whom stones either passed spontaneously or were removed by ureteroscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/38\">",
"       38",
"      </a>",
"      ]. Mass spectrometry demonstrated that the stones consisted of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"       indinavir",
"      </a>",
"      base monohydrate.",
"     </li>",
"     <li>",
"      In another study, among 240 patients, 8 percent experienced urologic symptoms and 3 percent had nephrolithiasis due to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"       indinavir",
"      </a>",
"      stones [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/30\">",
"       30",
"      </a>",
"      ]. In addition, among 142 patients who provided urine samples, 20 percent had urinary crystals consisting of indinavir (",
"      <a class=\"graphic graphic_picture graphicRef70939 \" href=\"mobipreview.htm?21/23/21877\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, one retrospective study of 24 patients with nephrolithiasis and HIV infection found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    containing stones were found in only 4 of 14 patients taking indinavir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/40\">",
"     40",
"    </a>",
"    ]. The other individuals had stones consisting of a variety of other substances (calcium oxalate and others), with metabolic evaluation suggesting a variety of abnormalities. This suggests that, among HIV patients administered indinavir, nephrolithiasis may result from something other than the protease inhibitor.",
"   </p>",
"   <p>",
"    The mechanism by which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    causes both AKI and nephrolithiasis is by the precipitation of indinavir crystals. Indinavir has a low solubility (0.03",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    at a pH of 6.0, but is much more soluble at lower pH values (100",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    at pH 3.5). In a study of 54 patients on indinavir, patients with urine pH &gt;6 were much more likely to have indinavir crystals on urinalysis than those with lower urinary pH, particularly if the urine was also concentrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/41\">",
"     41",
"    </a>",
"    ]. However, although acidification of urine may increase the solubility of indinavir, this is difficult to achieve and potentially harmful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/30,35,38\">",
"     30,35,38",
"    </a>",
"    ], thus acidification of urine is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased fluid intake prior to each oral dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    may decrease the risk of crystal formation. However, increased fluid intake may not be entirely protective. In a prospective study of 105 patients taking indinavir, a renal stone occurred in approximately 12 percent of patients after a median treatment duration of 22 weeks despite enhanced fluid intake documented by continuous monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The radiologic imaging procedures typically used in the diagnosis of ureteral stones appear to be",
"    <strong>",
"     unreliable",
"    </strong>",
"    in the diagnosis of nonopaque stones due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a retrospective study of 36 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    who presented with signs of renal colic (ipsilateral flank pain, dysuria, urgency, hematuria), abdominal radiography failed to identify a renal stone in any individual, while only 1 of 13 excretory urograms, 4 of 11 renal ultrasonographic examinations, and zero of 12 CT scans were diagnostic of nephrolithiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/42\">",
"     42",
"    </a>",
"    ]. Contrast-enhanced CT scanning may suggest the diagnosis by showing a filling defect in a ureter, delayed excretion, or a persistent nephrogram [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These renal and urologic complications with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    appear to require discontinuation of the agent in one-third of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/44\">",
"     44",
"    </a>",
"    ]. To help prevent nephrolithiasis and AKI, we suggest a daily oral fluid intake of at least 1.5 liters of water daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic kidney disease from protease inhibitors may also result from interstitial fibrosis and renal atrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/32-37\">",
"     32-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4164424\">",
"    <span class=\"h3\">",
"     Atazanavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    , the protease inhibitor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    , can lead to stone formation, and less commonly, AKI, due to its relative insolubility in the urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An initial case series described 11 patients who developed nephrolithiasis while taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/47\">",
"     47",
"    </a>",
"    ]. Analysis of the stones demonstrated crystals of atazanavir base but not metabolites. Eight stones contained a core of atazanavir; while four had a core of calcium oxalate (one patient had two stones).",
"   </p>",
"   <p>",
"    Several case reports and 30 cases of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    -associated nephrolithiasis were subsequently reported upon review of the FDA's Adverse Event Reporting System database [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/40,49\">",
"     40,49",
"    </a>",
"    ]. One study estimated a prevalence of atazanavir stones of 0.97 percent among those taking the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One case of AKI due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    -associated crystal nephropathy has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/50\">",
"     50",
"    </a>",
"    ]. In this case, rod-like atazanavir crystals were noted on urine microscopy (",
"    <a class=\"graphic graphic_picture graphicRef77620 \" href=\"mobipreview.htm?3/32/3584\">",
"     picture 3",
"    </a>",
"    ) as well as within tubular lumens and renal interstitium (along with granulomata) on renal biopsy (",
"    <a class=\"graphic graphic_picture graphicRef77824 \" href=\"mobipreview.htm?35/25/36246\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Fluid intake of at least 1.5",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    should be encouraged among patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1208776727\">",
"    <span class=\"h2\">",
"     Oxalate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury (AKI) due to oxalate deposition in the kidney has been described in several settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary hyperoxaluria (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12154?source=see_link\">",
"       \"Primary hyperoxaluria\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ethylene glycol poisoning (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/3/4154?source=see_link\">",
"       \"Methanol and ethylene glycol poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Secondary hyperoxaluria due to pancreatic insufficiency, inflammatory bowel disease, bowel resection, or gastric bypass (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18007?source=see_link\">",
"       \"Chronic complications of the short bowel syndrome in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"       Orlistat",
"      </a>",
"      therapy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/43/17081?source=see_link&amp;anchor=H18#H18\">",
"       \"Nephrocalcinosis\", section on 'Hyperoxaluria'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      High doses of vitamin C [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     Orlistat",
"    </a>",
"    , a weight loss drug that induces fat malabsorption, has been associated with intratubular calcium-oxalate deposition and AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/43/17081?source=see_link&amp;anchor=H18#H18\">",
"     \"Nephrocalcinosis\", section on 'Hyperoxaluria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4164440\">",
"    <span class=\"h2\">",
"     Oral sodium phosphate purgatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    preparations have been used as laxatives or purgatives for bowel cleansing before colonoscopy, computed tomographic virtual colonoscopy, or bowel surgery. AKI secondary to acute phosphate nephropathy has been reported following the use of oral sodium phosphate preparations. Acute phosphate nephropathy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7032?source=see_link\">",
"     \"Acute phosphate nephropathy\"",
"    </a>",
"    .)",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4164478\">",
"    <span class=\"h2\">",
"     Ciprofloxacin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The widely used fluoroquinolone antibiotic,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , is known to cause AKI from acute interstitial nephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Ciprofloxacin has also been reported to cause crystalluria in experimental animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/59\">",
"     59",
"    </a>",
"    ] and both crystalluria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/60-62\">",
"     60-62",
"    </a>",
"    ] and crystal-induced AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/63-67\">",
"     63-67",
"    </a>",
"    ] in humans. In all reports, patients developed oliguric AKI within two days to two weeks of ingestion of oral ciprofloxacin. All case reports except one, described patients who were 70 years or older and two described patients were on ACE inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/67\">",
"     67",
"    </a>",
"    ]. Urinalysis revealed crystals of varying shapes, which were composed of ciprofloxacin salt (",
"    <a class=\"graphic graphic_picture graphicRef50067 \" href=\"mobipreview.htm?21/16/21764\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    crystals typically precipitate in an alkaline pH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/60,68\">",
"     60,68",
"    </a>",
"    ]. However crystals have been described in association with acidic urine pH in several case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/63,66\">",
"     63,66",
"    </a>",
"    ]. Ciprofloxacin crystals have been shown to display a wide array of appearances including needles, sheaves, stars, fans, butterflies, and other unusual shapes. All crystals have had a lamellar structure, with sizes ranging from 30 x 5 &micro;m to 360 x 237 &micro;m, and are strongly birefringent under polarizing light [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/69\">",
"     69",
"    </a>",
"    ]. Histology obtained by renal biopsy in three patients revealed needle shaped birefringent crystals within the tubules (",
"    <a class=\"graphic graphic_picture graphicRef62878 \" href=\"mobipreview.htm?30/62/31719\">",
"     picture 6",
"    </a>",
"    ) without evidence of acute or chronic interstitial nephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. In all patients, renal function returned to baseline upon withdrawal of ciprofloxacin.",
"   </p>",
"   <p>",
"    Risk factors for AKI include impaired kidney function, volume depletion, and a urine pH above 6.0 (although acidic urine pH does not preclude a diagnosis of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    -induced crystal deposition). To prevent ciprofloxacin crystal-induced AKI, ciprofloxacin should be dose adjusted for level of GFR, the patient should be volume replete, and alkalinization of the urine should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/2/34857/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4164485\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute kidney injury (AKI) due to intratubular crystal precipitation is observed in association with many medications. Patients are generally asymptomatic although occasionally present with flank pain. Urinalysis may show hematuria, pyuria, and crystals with a characteristic morphology. (See",
"      <a class=\"local\" href=\"#H4164196\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4164210\">",
"       'Clinical presentation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The maintenance of optimal volume status and correction of volume depletion is critical in the prevention of crystal-induced AKI from all causes. The alkalinization of urine may help prevent crystal-induced AKI secondary to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/41/20118?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      antibiotics and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      . We suggest the following approach for patients who are receiving specific agents:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among patients who are receiving intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      , we suggest the administration of intravenous isotonic saline at a rate of 125",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      starting at least one hour prior to the administration of acyclovir and continuing for six hours after the acyclovir infusion is finished. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H101518418\">",
"       'Acyclovir'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients who are receiving high dose intravenous sulfonamide antibiotics and develop crystalluria, we suggest the administration of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      to prevent AKI (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4164288\">",
"       'Sulfonamide antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among all patients who are receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , we recommend the administration of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      to prevent AKI (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4164341\">",
"       'Methotrexate'",
"      </a>",
"      above.).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The maintenance of optimal volume status and correction of volume depletion is critical in the treatment of established AKI. Among all patients with established crystal-induced AKI from any cause, we recommend the correction of volume depletion with intravenous fluid (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In the absence of an indication for intravenous bicarbonate, such as for the treatment of sulfonamide- or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      -induced AKI, the preferred intravenous fluid is usually isotonic saline.",
"     </li>",
"     <li>",
"      A loop diuretic may be effective in clearing obstructing casts in crystal-induced AKI. Among all volume-replete patients with established crystal-induced AKI from any cause, we suggest administration of a loop diuretic (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Fluid loss induced by the diuretic must be replaced to prevent volume depletion and a late slowing of flow within the tubules. (See",
"      <a class=\"local\" href=\"#H4164217\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H101517554\">",
"       'Overview of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Crystals from sulfonamide antibiotics and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      are more likely to form in acidic urine. Alkalinization of urine may provide benefit in established AKI from sulfonamide antibiotics or methotrexate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among patients with established sulfonamide-associated AKI who are not oliguric and do not have hypocalcemia or metabolic alkalosis or an indication for acute hemodialysis, we suggest the administration of intravenous bicarbonate with a target urine pH of &gt;7.15 (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4164288\">",
"       'Sulfonamide antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with established",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      -associated AKI, who are not oliguric and do not have hypocalcemia or metabolic alkalosis or an indication for acute hemodialysis, we suggest the administration of intravenous bicarbonate with a target urine pH of &gt;7.0 (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4164341\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Crystals from protease inhibitors such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"       indinavir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      are more likely to form in alkaline urine. However it is difficult and potential dangerous to acidify the urine among patients with established AKI. We recommend NOT acidifying the urine for the treatment of crystal-induced AKI from any cause (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      -induced AKI often results in an elevated plasma methotrexate concentration which may increase the systemic toxicity of methotrexate.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       Leucovorin",
"      </a>",
"      rescue with or without thymidine or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"       glucarpidase",
"      </a>",
"      may be effective in this setting. (See",
"      <a class=\"local\" href=\"#H4164341\">",
"       'Methotrexate'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"       \"Major side effects of low-dose methotrexate\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=see_link&amp;anchor=H39#H39\">",
"       \"Therapeutic use and toxicity of high-dose methotrexate\", section on 'Glucarpidase (carboxypeptidase G2)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/1\">",
"      Perazella MA. Crystal-induced acute renal failure. Am J Med 1999; 106:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/2\">",
"      Teichman JM. Clinical practice. Acute renal colic from ureteral calculus. N Engl J Med 2004; 350:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/3\">",
"      Sawyer MH, Webb DE, Balow JE, Straus SE. Acyclovir-induced renal failure. Clinical course and histology. Am J Med 1988; 84:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/4\">",
"      Berns JS, Cohen RM, Stumacher RJ, Rudnick MR. Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections. J Am Soc Nephrol 1991; 1:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/5\">",
"      Brigden D, Rosling AE, Woods NC. Renal function after acyclovir intravenous injection. Am J Med 1982; 73:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/6\">",
"      Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Arch Intern Med 1995; 155:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/7\">",
"      Krieble BF, Rudy DW, Glick MR, Clayman MD. Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis. Am J Med Sci 1993; 305:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/8\">",
"      Obada EN, Level G, Mathieu P, et al. [Acute renal failure following a treatment with acyclovir]. Nephrol Ther 2010; 6:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/9\">",
"      Giustina A, Romanelli G, Cimino A, Brunori G. Low-dose acyclovir and acute renal failure. Ann Intern Med 1988; 108:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/10\">",
"      Eck P, Silver SM, Clark EC. Acute renal failure and coma after a high dose of oral acyclovir. N Engl J Med 1991; 325:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/11\">",
"      Spiegal DM, Lau K. Acute renal failure and coma secondary to acyclovir therapy. JAMA 1986; 255:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/12\">",
"      Cohen SM, Minkove JA, Zebley JW 3rd, Mulholland JH. Severe but reversible neurotoxicity from acyclovir. Ann Intern Med 1984; 100:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/13\">",
"      Simon DI, Brosius FC 3rd, Rothstein DM. Sulfadiazine crystalluria revisited. The treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. Arch Intern Med 1990; 150:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/14\">",
"      Carbone LG, Bendixen B, Appel GB. Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome. Am J Kidney Dis 1988; 12:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/15\">",
"      Hein R, Brunkhorst R, Thon WF, et al. Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases. Clin Nephrol 1993; 39:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/16\">",
"      Sasson JP, Dratch PL, Shortsleeve MJ. Renal US findings in sulfadiazine-induced crystalluria. Radiology 1992; 185:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/17\">",
"      Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005; 84:377.",
"     </a>",
"    </li>",
"    <li>",
"     Garrick, MB, Mayer, RJ, Abelson, HT. Acute renal failure associated with cancer treatment. In: Acute Renal Failure, 2nd ed, Brenner, BM, Lazarus, JM (Eds), Churchill Livingstone, New York 1988. p.636.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/19\">",
"      Pitman SW, Frei E 3rd. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. Cancer Treat Rep 1977; 61:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/20\">",
"      Abelson HT, Fosburg MT, Beardsley GP, et al. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1983; 1:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/21\">",
"      Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006; 11:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/22\">",
"      Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004; 100:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/23\">",
"      Krause AS, Weihrauch MR, Bode U, et al. Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy. Leuk Lymphoma 2002; 43:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/24\">",
"      Widemann BC, Balis FM, Murphy RF, et al. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol 1997; 15:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/25\">",
"      Buchen S, Ngampolo D, Melton RG, et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 2005; 92:480.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125327lbl.pdf?et_cid=28599956&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f125327lbl.pdf (Accessed on January 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/27\">",
"      Garella S. Extracorporeal techniques in the treatment of exogenous intoxications. Kidney Int 1988; 33:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/28\">",
"      Wall SM, Johansen MJ, Molony DA, et al. Effective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis 1996; 28:846.",
"     </a>",
"    </li>",
"    <li>",
"     Pasko, DA, Grio, M, Thomas, S, et al. Methotrexate transmembrane clearance during albumin based continuous veno-venous hemodialysis. Blood Purif 2005; 23:165.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/30\">",
"      Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997; 127:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/31\">",
"      Gagnon RF, Tecimer SN, Watters AK, Tsoukas CM. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis 2000; 36:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/32\">",
"      Jao J, Wyatt CM. Antiretroviral medications: adverse effects on the kidney. Adv Chronic Kidney Dis 2010; 17:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/33\">",
"      Tashima KT, Horowitz JD, Rosen S. Indinavir nephropathy. N Engl J Med 1997; 336:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/34\">",
"      Martinez F, Mommeja-Marin H, Estepa-Maurice L, et al. Indinavir crystal deposits associated with tubulointerstitial nephropathy. Nephrol Dial Transplant 1998; 13:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/35\">",
"      Perazella MA, Kashgarian M, Cooney E. Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Clin Nephrol 1998; 50:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/36\">",
"      Sarcletti M, Petter A, Romani N, et al. Pyuria in patients treated with indinavir is associated with renal dysfunction. Clin Nephrol 2000; 54:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/37\">",
"      Daugas E, Rougier JP, Hill G. HAART-related nephropathies in HIV-infected patients. Kidney Int 2005; 67:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/38\">",
"      Daudon M, Est&eacute;pa L, Viard JP, et al. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 1997; 349:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/39\">",
"      Reiter WJ, Sch&ouml;n-Pernerstorfer H, Dorfinger K, et al. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J Urol 1999; 161:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/40\">",
"      Nadler RB, Rubenstein JN, Eggener SE, et al. The etiology of urolithiasis in HIV infected patients. J Urol 2003; 169:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/41\">",
"      Gagnon RF, Alli AI, Edwardes MD, et al. Low urine pH is associated with reduced indinavir crystalluria in indinavir-treated HIV-infected individuals. Clin Nephrol 2006; 65:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/42\">",
"      Schwartz BF, Schenkman N, Armenakas NA, Stoller ML. Imaging characteristics of indinavir calculi. J Urol 1999; 161:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/43\">",
"      Blake SP, McNicholas MM, Raptopoulos V. Nonopaque crystal deposition causing ureteric obstruction in patients with HIV undergoing indinavir therapy. AJR Am J Roentgenol 1998; 171:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/44\">",
"      Voigt E, Wickesberg A, Wasmuth JC, et al. First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results. HIV Med 2002; 3:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/45\">",
"      Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/46\">",
"      Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 2004; 44:e81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/47\">",
"      Couzigou C, Daudon M, Meynard JL, et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis 2007; 45:e105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/48\">",
"      Chang HR, Pella PM. Atazanavir urolithiasis. N Engl J Med 2006; 355:2158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/49\">",
"      Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS 2007; 21:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/50\">",
"      Izzedine H, M'rad MB, Bardier A, et al. Atazanavir crystal nephropathy. AIDS 2007; 21:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/51\">",
"      Swartz RD, Wesley JR, Somermeyer MG, Lau K. Hyperoxaluria and renal insufficiency due to ascorbic acid administration during total parenteral nutrition. Ann Intern Med 1984; 100:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/52\">",
"      Nakamoto Y, Motohashi S, Kasahara H, Numazawa K. Irreversible tubulointerstitial nephropathy associated with prolonged, massive intake of vitamin C. Nephrol Dial Transplant 1998; 13:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/53\">",
"      Courtney AE, O'Rourke DM, Maxwell AP. Rapidly progressive renal failure associated with successful pharmacotherapy for obesity. Nephrol Dial Transplant 2007; 22:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/54\">",
"      Singh A, Sarkar SR, Gaber LW, Perazella MA. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis 2007; 49:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/55\">",
"      Weir MA, Beyea MM, Gomes T, et al. Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med 2011; 171:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/56\">",
"      Hootkins R, Fenves AZ, Stephens MK. Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature. Clin Nephrol 1989; 32:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/57\">",
"      Connor JP, Curry JM, Selby TL, Perlmutter AD. Acute renal failure secondary to ciprofloxacin use. J Urol 1994; 151:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/58\">",
"      Markowitz GS, Perazella MA. Drug-induced renal failure: a focus on tubulointerstitial disease. Clin Chim Acta 2005; 351:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/59\">",
"      Ball P. Ciprofloxacin: an overview of adverse experiences. J Antimicrob Chemother 1986; 18 Suppl D:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/60\">",
"      Thorsteinsson SB, Bergan T, Oddsdottir S, et al. Crystalluria and ciprofloxacin, influence of urinary pH and hydration. Chemotherapy 1986; 32:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/61\">",
"      Thorsteinsson SB, Bergan T, Rohwedder R. Tolerance of intravenously administered ciprofloxacin. Chemotherapy 1988; 34:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/62\">",
"      Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Saf 1995; 13:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/63\">",
"      Chopra N, Fine PL, Price B, Atlas I. Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation. J Urol 2000; 164:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/64\">",
"      Dharnidharka VR, Nadeau K, Cannon CL, et al. Ciprofloxacin overdose: acute renal failure with prominent apoptotic changes. Am J Kidney Dis 1998; 31:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/65\">",
"      Sedlacek M, Suriawinata AA, Schoolwerth A, Remillard BD. Ciprofloxacin crystal nephropathy--a 'new' cause of acute renal failure. Nephrol Dial Transplant 2006; 21:2339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/66\">",
"      Stratta P, Lazzarich E, Canavese C, et al. Ciprofloxacin crystal nephropathy. Am J Kidney Dis 2007; 50:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/67\">",
"      Montagnac R, Briat C, Schillinger F, et al. [Fluoroquinolone induced acute renal failure. General review about a case report with crystalluria due to ciprofloxacin]. Nephrol Ther 2005; 1:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/68\">",
"      Schluter G. Ciprofloxacin: toxicologic evaluation of additional safety data. Am J Med 1989; 87:37S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/69\">",
"      Fogazzi GB, Garigali G, Brambilla C, Daudon M. Ciprofloxacin crystalluria. Nephrol Dial Transplant 2006; 21:2982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/2/34857/abstract/70\">",
"      Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis 1988; 10 Suppl 1:S141.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7229 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_2_34857=[""].join("\n");
var outline_f34_2_34857=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4164485\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4164196\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4164203\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4164210\">",
"      CLINICAL PRESENTATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4164217\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101517554\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4164281\">",
"      SPECIFIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H101518418\">",
"      Acyclovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4164288\">",
"      Sulfonamide antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4164341\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4164392\">",
"      Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4164400\">",
"      - Indinavir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4164424\">",
"      - Atazanavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1208776727\">",
"      Oxalate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4164440\">",
"      Oral sodium phosphate purgatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4164478\">",
"      Ciprofloxacin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4164485\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7229\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7229|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/33/14865\" title=\"picture 1\">",
"      Sulfa crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/23/21877\" title=\"picture 2\">",
"      Indinavir crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/32/3584\" title=\"picture 3\">",
"      Urine sediment of a pt with atazanavir crystalluria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/25/36246\" title=\"picture 4\">",
"      Renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/16/21764\" title=\"picture 5\">",
"      Cipro crystalluria shapes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/62/31719\" title=\"picture 6\">",
"      Cipro crystals kidney bx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7032?source=related_link\">",
"      Acute phosphate nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18007?source=related_link\">",
"      Chronic complications of the short bowel syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/3/4154?source=related_link\">",
"      Methanol and ethylene glycol poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/43/17081?source=related_link\">",
"      Nephrocalcinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12154?source=related_link\">",
"      Primary hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=related_link\">",
"      Therapeutic use and toxicity of high-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_2_34858="EPS tracing AVNRT dual AVN pathways I";
var content_f34_2_34858=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60369%7ECARD%2F72161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60369%7ECARD%2F72161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 597px\">",
"   <div class=\"ttl\">",
"    Electrophysiologic study (EPS) in a patient with atrioventricular nodal reentrant tachycardia and dual AV nodal pathways",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 577px; height: 448px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tracing shows three surface ECG leads (I, II, V1) and intracardiac recordings from the high right atrium (HRA), bundle of His (HIS), right ventricular apex (RVA), and coronary sinus (CS). During atrial pacing (S1) at a cycle length of 600 ms (100 beats per minute); the AH interval is 120 ms. An atrial premature beat (S2) is added at a coupling cyle of 420 ms; this results in a prolongation of the PR interval and increase in the AH interval to 184 ms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin Burke, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 575px\">",
"   <div class=\"ttl\">",
"    Electrophysiologic study (EPS) in a patient with atrioventricular nodal reentrant tachycardia and dual AV nodal pathways",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 555px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tracing shows three surface ECG leads (I, II, V1) and intracardiac recordings from the high right atrium (HRA), bundle of His (HIS), right ventricular apex (RVA), and coronary sinus (CS). During atrial pacing (S1) at a cycle length of 600 ms (100 beats per minute); the AH interval is 120 ms. An atrial premature beat (S2) is added at a coupling cyle of 410 ms; this results in a prolongation of the PR interval and increase in the AH interval to 242 ms, which represents a 60 ms increase compared to the AH when a premature beat was added with a coupling interval of 420 ms. This represents a \"jump\" due to a shift of AV nodal conduction from the fast to slow AV nodal pathway. Since the fast pathway has time to recover, there is retrograde VA conduction via the fast pathway, resulting in the occurrence of a retrograde His depolarization (HIS \"A\") and an atrial echo beat at the CS os area (CS 10-9).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin Burke, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_2_34858=[""].join("\n");
var outline_f34_2_34858=null;
var title_f34_2_34859="ACC AHA preop LV function";
var content_f34_2_34859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Preoperative noninvasive evaluation of left ventricular (LV) function",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIa - The evidence or opinion is in favor of benefit from preoperative noninvasive evaluation of LV function prior to noncardiac surgery in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Patients with dyspnea of unknown origin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Patients with current or prior heart failure with worsening dyspnea or other changes in clinical status who have not undergone testing within 12 months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIb - The weight of evidence or opinion is less well established for the benefit of preoperative noninvasive evaluation of LV function",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Routine evaluation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class III - There is evidence and/or general agreement that preoperative noninvasive evaluation of LV function prior to noncardiac surgery is not useful in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Routine testing",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol 2007; 50:e159.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_2_34859=[""].join("\n");
var outline_f34_2_34859=null;
var title_f34_2_34860="DSM-IV-TR diagnostic criteria for acute stress disorder";
var content_f34_2_34860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F70263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F70263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR diagnostic criteria for acute stress disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         A.",
"        </strong>",
"        The person has been exposed to a traumatic event in which both of the following were present:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ol>",
"         <li>",
"          The person experienced, witnessed, or was confronted with an event or events that involved actual or threatened death or serious injury, or a threat to the physical integrity of self or others",
"         </li>",
"         <li>",
"          The person's response involved intense fear, helplessness, or horror",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         B.",
"        </strong>",
"        Either while experiencing or after experiencing the distressing event, the individual has three (or more) of the following dissociative symptoms:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ol>",
"         <li>",
"          A subjective sense of numbing, detachment, or absence of emotional responsiveness",
"         </li>",
"         <li>",
"          A reduction in awareness of his or her surroundings (eg, \"being in a daze\")",
"         </li>",
"         <li>",
"          Derealization",
"         </li>",
"         <li>",
"          Depersonalization",
"         </li>",
"         <li>",
"          Dissociative amnesia (ie, inability to recall an important aspect of the trauma)",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         C.",
"        </strong>",
"        The traumatic event is persistently reexperienced in at least one of the following ways: recurrent images, thoughts, dreams, illusions, flashback episodes, or a sense of reliving the experience; or distress on exposure to reminders of the traumatic event",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         D.",
"        </strong>",
"        Marked avoidance of stimuli that arouse recollections of the trauma (eg, thoughts, feelings, conversations, activities, places, people)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         E.",
"        </strong>",
"        Marked symptoms of anxiety or increased arousal (eg, difficulty sleeping, irritability, poor concentration, hypervigilance, exaggerated startle response, motor restlessness)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         F.",
"        </strong>",
"        The disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning or impairs the individual's ability to pursue some necessary task, such as obtaining necessary assistance or mobilizing personal resources by telling family members about the traumatic experience",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         G.",
"        </strong>",
"        The disturbance lasts for a minimum of 2 days and a maximum of 4 weeks and occurs within 4 weeks of the traumatic event",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         H.",
"        </strong>",
"        The disturbance is not due to the direct physiological effects of a substance (eg, a drug of abuse, a medication) or a general medical condition, is not better accounted for by Brief Psychotic Disorder, and is not merely an exacerbation of a preexisting Axis I or Axis II disorder",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (Copyright 2000). American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_2_34860=[""].join("\n");
var outline_f34_2_34860=null;
var title_f34_2_34861="Criteria for SSI";
var content_f34_2_34861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for defining a surgical site infection (SSI)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Superficial incisional SSI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection occurs within 30 days after the operation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         AND",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection involves only skin or subcutaneous tissue of the incision",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         AND",
"        </strong>",
"        at least",
"        <strong>",
"         ONE",
"        </strong>",
"        of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Purulent drainage, with or without laboratory confirmation, from the superficial incision.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. At least one of the following signs or symptoms of infection: pain or tenderness, localized swelling, redness, or heat",
"        <strong>",
"         AND",
"        </strong>",
"        superficial incision is deliberately opened by surgeon,",
"        <strong>",
"         UNLESS",
"        </strong>",
"        incision is culture-negative.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Diagnosis of superficial incisional SSI by the surgeon or attending physician.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Do",
"        <strong>",
"         NOT",
"        </strong>",
"        report the following conditions as SSI:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Stitch abscess (minimal inflammation and discharge confined to the points of suture penetration).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Infection of an episiotomy or newborn circumcision site.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Infected burn wound.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Incisional SSI that extends into the fascial and muscle layers (see deep incisional SSI).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Note: Specific criteria are used for identifying infected episiotomy and circumcision sites and burn wounds.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Deep incisional SSI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection occurs within 30 days after the operation if no implant* is left in place or within 1 year if implant is in place and the infection appears to be related to the operation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         AND",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection involves deep soft tissues (eg, fascial and muscle layers) of the incision",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         AND",
"        </strong>",
"        at least",
"        <strong>",
"         ONE",
"        </strong>",
"        of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Purulent drainage from the deep incision but not from the organ/space component of the surgical site.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. A deep incision spontaneously dehisces or is deliberately opened by a surgeon when the patient has at least one of the following signs or symptoms: fever (&gt;38&deg;C), localized pain, or tenderness, unless site is culture-negative.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. An abscess or other evidence of infection involving the deep incision is found on direct examination, during reoperation, or by histopathologic or radiologic examination.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Diagnosis of a deep incisional SSI by a surgeon or attending physician.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Notes:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Report infection that involves both superficial and deep incision sites as deep incisional SSI.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Report an organ/space SSI that drains through the incision as a deep incisional SSI.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Organ/space SSI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection occurs within 30 days after the operation if no implant* is left in place or within 1 year if implant is in place and the infection appears to be related to the operation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         AND",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Infection involves any part of the anatomy (eg, organs or spaces), other than the incision, which was opened or manipulated during an operation and at least one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Purulent drainage from a drain that is placed through a stab wound",
"        <sup>",
"         &bull;",
"        </sup>",
"        . If the area around a stab wound becomes infected, it is not an SSI. It is considered a skin or soft tissue infection, depending on its depth into the organ/space.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Organisms isolated from an aseptically obtained culture of fluid or tissue in the organ/space.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. An abscess or other evidence of infection involving the organ/space that is found on direct examination, during reoperation, or by histopathologic or radiologic examination.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Diagnosis of an organ/space SSI by a surgeon or attending physician.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * National Nosocomial Infection Surveillance definition: a nonhuman-derived implantable foreign body (eg, prosthetic heart valve, nonhuman vascular graft, mechanical heart, or hip prosthesis) that is permanently placed in a patient during surgery.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      If the area around a stab wound becomes infected, it is not an SSI. It is considered a skin or soft tissue infection, depending on its depth.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection. In: Infection Control and Hospital Epidemiology, CDC 1999; 20:247.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_2_34861=[""].join("\n");
var outline_f34_2_34861=null;
var title_f34_2_34862="SPEP in WM";
var content_f34_2_34862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Serum protein electrophoresis in Waldenstr&ouml;m macroglobulinemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 236px; height: 417px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The figure shows a serum protein electrophoresis (SPEP) pattern in a patient with Waldenstr&ouml;m macroglobulinemia with a monoclonal (M) protein in the gamma region (asterisk). Immunofixation (IFE) shows that the M protein is IgM kappa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_2_34862=[""].join("\n");
var outline_f34_2_34862=null;
var title_f34_2_34863="Cormack Lehane laryngoscopy grade";
var content_f34_2_34863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Cormack-Lehane grading scheme for laryngoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Difficulty of direct laryngoscopy correlates with the best view of the glottis, as defined by the Cormack-Lehane scale. With this scale, a grade one view connotes a full view of the entire glottic aperture, grade two represents a partial glottic view, grade three represents visualization of the epiglottis only, and grade four represents inability to visualize even the epiglottis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_2_34863=[""].join("\n");
var outline_f34_2_34863=null;
